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ABSTRACT
Wound care affects millions of people worldwide each year, and the need for an
effective wound therapy still exists. The aim of this study was to characterize a novel,
aerated biopolymer, fibrin foam, which is generated through a patented mixing process
using a commercially-available fibrin sealant. This research developed a distinct
preparation of fibrin foam that creates a porous environment with improved wound
healing properties. With this fibrin foam, characterization assessments were performed,
including evaluation of mixing parameters, biocompatibility, and biomechanical
strengths.
Fibrin foam is created by performing six passes through a mixing device, which
generates a foam matrix with a mean pore size of 155 micrometers. Cellular viability
assays utilizing lactate dehydrogenase and AlamarBlue reagents demonstrated that
primary endothelial cells, fibroblasts, and keratinocytes were all viable and metabolically
active on and within fibrin foam. Though fibrin foam produced slightly weaker tensile
and wound closure strengths from a biomechanical standpoint compared to the fibrin
sealant, the aeration process provides additional structural properties. These include
higher fluid permeability and greater porosity.
In addition to characterizing the biodegradable fibrin foam, efficacy was assessed
in an in vivo wound healing model. For this, a biopsy punch model was utilized whereby
full-thickness dorsal skin wounds were generated in mice. The wounds were treated with
fibrin foam, and wounds were evaluated 7 and 14 days post-surgery. The fibrin foamxii

treated wounds showed significantly superior wound closure compared to the other
treatments. In summary, this study characterized an aerated fibrin preparation generated
from a commercially-available fibrin sealant and demonstrated its superior efficacy as a
novel wound therapy.

xiii

CHAPTER ONE
INTRODUCTION
Wound care has evolved substantially over the years for the treatment of patients
worldwide. The annual global prevalence of skin wounds is staggering – 114 million
acute wounds, 40 million chronic wounds, and over 10 million burn wounds.1,2 These
wounds have a major clinical and economic impact on the patients. To treat and close
wounds, a number of options are available, including sutures, staples, surgical sealants
and glues, and energy- and negative-pressure-based wound closure techniques.3-5 These
products and procedures are designed to facilitate the multiphase wound healing process.
Wound healing consists of four main stages – hemostasis, inflammation, proliferation,
and remodeling.6,7 However, complications of wound healing can arise and range from
pain, scarring, and dehiscence to the more severe evisceration, hemorrhage, and
infection.8,9
More recent wound care treatments have progressed to aid in more efficacious
wound healing and to avoid the consequences of improper or impaired wound healing.
Modern wound care treatments include stem cell treatment, gene therapy, and lightemitting diode-based treatment; however, these are still in early development.1 One
particular wound healing advancement, tissue engineering, seeks to mimic regeneration
by employing bioengineered scaffolds to create suitable cellular microenvironments. The
optimal matrix should have the following characteristics: 1) biocompatible; 2)
biodegradable; 3) allows for cellular infiltration; 4) allows for gas and fluid transfer; 5)
1
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antibacterial/antimicrobial; 6) strength to resist shear and fragmentation stresses; 7)
reduces heal-time; and 8) fully-incorporates into surrounding tissue.10-12 Current tissue
engineering scaffolds have been developed from materials, such as collagen, hyaluronic
acid, polyesters, acellular matrices, and fibrin – each with their respective advantages and
disadvantages.13-15
Fibrin has been well-characterized as a therapy in hemostasis and wound healing.
Fibrin also has a critical role in cellular and matrix interactions, inflammation,
angiogenesis, and neoplasia.16 This is due to its inherent binding sites for cellular
receptors, integrins, and clotting and growth factors.17-19 By having a dual function of
contributing to the biologically active clot during hemostasis and creating a viable matrix
with specific-binding sites during the wound healing process, fibrin is crucial to tissue
repair.20-22 Thus, fibrin sealants have been investigated as scaffolds to promote wound
healing.
ARTISS is a fibrin sealant indicated for use as a tissue glue to adhere/seal
subcutaneous tissue in plastic, reconstructive, and burn surgeries, as a replacement or an
adjunct treatment. Additionally, ARTISS is indicated as an adjunct to hemostasis on
subcutaneous tissue surfaces.23 Fibrin foam is a novel fibrin biopolymer that is generated
when ARTISS is aerated using a patented mixing process.24-28 Compared to ARTISS,
fibrin foam has greater viscosity, can polymerize in a temperature-independent manner,
and can be applied to both vertical and inverted surfaces without dripping. Additionally,
the foam mixing process generates an open-pore fibrin clot structure compared to the
dense, closed structure of typical fibrin sealants.24-27
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This prior research has presented fibrin foam as a candidate for uses in specific
surgical procedures, including acute and chronic wound treatments, where standard tissue
sealants have historically had poor performance. Based on these preliminary findings, I
hypothesized that this novel fibrin sealant preparation would gain advantageous physical
attributes from aeration, which would allow fibrin foam to function as a superior wound
therapy. Therefore, this study set out to characterize fibrin foam.
The first aim of this study was to determine the impact of aeration on the physical,
biomechanical, and biocompatibility properties of fibrin foam. The process and
formulation for fibrin foam were initially tested to generate an optimal foam. From here,
I used the optimal foam in additional characterization experiments. Biomechanical and
structural attributes were measured, including tensile strength, porosity, and permeability.
To determine the biocompatibility of fibrin foam, both qualitative (scanning electron and
confocal microscopies) and quantitative (lactate dehydrogenase and AlamarBlue assays)
experiments were used.
The second aim of the study focused on the use of fibrin foam as a novel wound
therapy. Utilizing an in vitro three-dimensional assay to mimic a wound, I was able to
visually assess cellular migration and proliferation on and within fibrin foam. Moving
from these results, a murine skin wound model was used to elucidate the in vivo efficacy
and performance of fibrin foam as a wound therapy. Lastly, fibrin foam was tested for its
use and feasibility in a negative-pressure wound therapy system.
Results from this work indicate that fibrin foam is a biodegradable and
biocompatible polymer with advantageous structural characteristics. Fibrin foam was
also shown to be effective in the three-dimensional in vitro wound model as well as
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having superior wound-closure ability in the murine model. Following this study, it can
be established that fibrin foam is an appropriate candidate for future research as a novel
wound healing therapy.

CHAPTER TWO
LITERATURE REVIEW
Skin and Wounds.
The skin is a multilayered organ within the integumentary system. It is the largest
organ in this system and is important in the balance of human health and disease. The
skin contains three, main layers within its structure (Fig. 1). They are the epidermis,
dermis, and hypodermis (or subcutaneous layer).1,3 The epidermis is the outer most layer
of the skin and is divided into five additional layers. The stratum corneum is the top
layer of the epidermis and contains mainly flat squamous cells and keratinocytes. These
cells serve as a barrier to prevent water loss and entrance of bacteria into the host system.
The stratum lucidum is a layer present only in human palms and soles; it is composed of
several layers of dead cells, which act as an additional barrier. The next layer of the
epidermis is the stratum granulosum. This thin, granular layer of cells is important in the
secretion of lamellar granules, which aid in the binding of keratin fibers. Specialized
cuboidal cells interacting with desmosomes are found in the stratum spinosum. This
layer contains multiple layers of keratins that support the epidermal layer. The last and
deepest layer in the epidermis is known at the stratum basale. This layer is comprised of
columnar cells that are continuously undergoing cell division and proliferation into new
keratinocytes. The stratum basale also contains melanocytes and Langerhans cells, which
are important in the skin’s overall immune function.4,5,29

5
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Figure 1. Anatomy of the Skin. The skin is composed of two main layers. First, the
epidermis, which is comprised of closely-packed epithelial cells, and secondly, the
dermis, made of dense, irregular connective tissue. The dermis houses hair follicles,
sweat glands, blood vessels, and other structures. The subcutaneous tissue lies underneath
the dermis, which is composed mainly of adipose and underlying connective tissues.
Adapted from Grice et al.30
The dermis is the next layer in human skin. This middle layer contains many
more cells and cellular elements than the epidermis. Collagen and elastin as well as other
connective tissues are housed within the dermis. Cells, such as fibroblasts, are located
here as well. Hair follicles, nerves, lymphatic and blood vessels, and sweat and
sebaceous glands are also found in this layer. The dermis acts to cushion the skin from
external forces and also eliminates waste. The bottommost layer of the skin is the
hypodermis, or subcutis/subcutaneous tissue layer. The subcutaneous layer is comprised
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of adipose tissue. These deposits of fat allow for the protection from external injury as
well as insulation of body heat.29 This is the final layer before reaching the underlying
muscle, bone, and ligaments.
These combined layers of the skin have a multitude of functions that are vital to
the human body. Externally, the skin provides protection from foreign objects as well as
ultraviolet radiation. The dermal layer regulates temperature by either dilating or
constricting the blood vessels, which are innervated by the sympathetic nervous system.
Langerhans cells within the epidermis are important in recognition of microbial antigens
in support of our immune system. Additionally, the skin has functions in insulation and
storage of fat tissues, sensations of external movements, and internal vitamin D
synthesis.31-33
While the skin serves as a protective barrier, it can be subjected to injury in the
form of a wound. These disruptions of the skin can be classified as acute (surgical or
traumatic) or chronic (pressure or diabetic) wounds. The annual global prevalence of
these skin wounds is astounding with 114 million acute wounds, 40 million chronic
wounds, and over 10 million burn-related wounds.1 In the United States alone, these
numbers are overwhelming. In 2009, there were a reported 60 million major and minor
wound incidents, 13 million traumatic wounds, and 4 million pressure- and ulcer-causing
wounds.2 Each year since, these numbers have been growing with the increases in the
aged population as well as the increased incidence of diabetes and obesity worldwide.
The first two cases of wounds – surgical and traumatic – are acute wounds and are
typically classified based on their etiology. Surgical wounds occur as a result of a cut
due to a sharp instrument, which often occurs during a surgical procedure. Traumatic
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wounds include lacerations (tissues are torn apart), abrasions (wound results from friction
or scraping away) and contusions (wound results from a direct blow). Included in the
traumatic grouping are also burn wounds, amputations, and the more rare disorders, such
as necrotizing fasciitis.8,34
Chronic wounds typically persist for significant amounts of time, can reoccur, and
can develop deep within soft tissues. Within the chronic wound classification are
pressure ulcers, diabetic ulcers, and venous and arterial ulcers. These wounds manifest
upon one or more of the following factors: lack of blood flow, malnutrition, trauma,
immobility, excessive moisture, and lack of sensation. Pressure ulcers are the most
common chronic wound and result in tissue ischemia after long periods of applied
pressure to a tissue.1 Venous ulcers can be caused by several conditions including, deep
vein thrombosis, peripheral neuropathy, and obesity. Arterial ulcers are often caused by
diabetes mellitus, aging, and peripheral vascular disease. However, these are commonly
treated with surgical intervention or pharmaceuticals. The final classification of chronic
wounds is diabetic ulcers. Due to irregular blood glucose levels and impaired immune
defenses, diabetic patients are often prone to this type of chronic ulcer. Diabetic ulcers
can manifest on the lower limbs and feet of patients and heal slowly and poorly due to the
delayed healing and infection-prone phenotype of diabetic patients.2,3
Proper therapies are in place to treat both acute and chronic wounds; however,
complications can arise within a wound. When wounds fail to heal properly, minor
adverse effects, such as scars and dehiscence, can occur. Scars are a naturally occurring
process of wound healing; however, abnormal scarring can result in the formation of
keloid or hypertrophic scars, which are caused by excessive inflammatory response and
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fibrin formation.1 Dehiscence is the partial or total splitting open, or separation, of
wound layers. This most commonly occurs before collagen formation and can also be
caused while removing particular wound healing treatments, such as sutures. More
severe consequences include hemorrhage and infection. Hemorrhage occurs when the
initial phase of hemostasis is unable to stop the bleeding. This can be caused by a slipped
surgical suture, a dislodged clot, infection or erosion of a blood vessel by a foreign
object. Lastly, infections, which can be quite serious, are a significant detriment to the
wound healing process. Bacterial infections can inhibit wound healing and can lead to
discomfort, deformity, disability, and even death.4,5
Wound Healing.
The human body begins to heal wounds within seconds after the insult or injury.
Wound healing is a multi-phase process that includes the processes of hemostasis,
inflammation, proliferation, and remodeling/maturation (Fig. 2).6,7,9 However, wound
healing is much more complex than the simple progression of phases details. There is
extensive overlap between the phases, and within each phase, there are a plethora of
reactions occurring among the cells, matrices, and chemical mediators (Fig. 3).35
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Figure 2. Phases of Wound Healing. The sequential wound healing process with its
four main phases, including hemostasis, inflammation, proliferation, and remodeling.
Collagen exposed during wound formation activates hemostasis and the inflammatory
phase. The fibrin clot formed during hemostasis serves as a scaffold for cells, such as
neutrophils, monocytes, fibroblasts, and endothelial cells. Fibrin also serves to
concentrate the influx of cytokines and growth factors. During the proliferation phase,
processes, such as epithelialization, angiogenesis, and granulation tissue formation are
rapidly occurring. Lastly, in the remodeling phase, collagen deposition into wellorganized networks occurs for up to a year following wounding. Adapted from
Broughton et al.36
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The initial step in the wound healing process is hemostasis. Hemostasis begins
immediately after the injury has occurred, resulting in blood vessel constriction.37
Following this vasoconstriction, two simultaneous reactions begin to generate a clot at
the wound site. The extrinsic pathway of the coagulation cascade is activated and leads
to the generation of a stabilized fibrin clot. At the same time, local endothelium and
platelets become active and aggregate. This platelet aggregation forms a physical barrier
to prevent further blood loss. Once this clot has been generated, the fibrin, platelets,
collagen, and other factors begin to release cytokines and growth factors into the
interstitium. The clot also serves as a vital scaffold for incoming cells, such as
fibroblasts, neutrophils, monocytes, and endothelial cells.18
After injury and following the formation of the clot, inflammatory factors and
mediators are released from cellular membranes and clotting factors at the wound site.7
Blood vessel dilation leads to the accumulation of these factors and results in overall
inflammation. Neutrophils will next enter the wound site and begin to eradicate bacteria
and cellular debris. Metalloproteinases remove damaged extracellular matrix from the
wound site to clear the way for new cellular structures. Lastly, macrophages begin to
work within the wound cavity.38 Macrophages secrete enzymes and cytokines, such as
vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF), which
stimulate debridement of the wound, promotion of angiogenesis, and proliferation of
keratinocytes.39,40 These actions by the macrophages serve as a crucial gateway into the
third phase of wound healing – proliferation.
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Proliferation occurs at the wound site from approximately day 4 through day 14
post-wounding. The key processes of epithelialization, angiogenesis, granulation tissue
formation, and collagen deposition occur throughout these days (Fig. 3).36

Figure 3. Wound Environment and Key Players. The key players within the wound
environment. (Top) Within minutes after wounding, coagulation occurs and the fibrin
clot is formed within the wound cavity. Inflammation is induced, characterized by entry
of neutrophils and macrophage accumulation. (Bottom) Fibroblasts enter the region in
subsequent days. Granulation tissue is established and angiogenesis occurs. In the final
steps, epithelialization is initiated, collagen is deposited, and the extracellular matrix
undergoes remodeling. Adapted from Broughton et al.7
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Epithelialization is stimulated during the inflammatory phase and begins shortly
thereafter. Fibroblasts that entered the wound as a result of macrophage stimulation
begin to secrete keratinocyte growth factor (KGF).40 This factor stimulates the nearby
keratinocytes to migrate into the wound area, proliferate, and differentiate into new
extracellular matrix and epidermis. Endothelial cells and fibroblasts have additional roles
within the proliferation phase. Stimulated endothelial cells begin to form new blood
vessels within the wounded region as part of angiogenesis. Within the final portion of the
proliferation phase, migrated fibroblasts will become activated, proliferate, and begin to
synthesize collagen and form granulation tissue. Collagen deposition begins and is the
transitional step into the final phase of wound healing, maturation and remodeling.
As the name implies, remodeling and organization of the collagen matrix is the
key aspect of this phase. The initial granulation tissue and collagen results in thin strands,
which are not highly organized. As the weeks progress, however, the thin collagen fibers
are reabsorbed and thicker, denser collagen is deposited into the wound by fibroblasts.
Maturation and remodeling begins to occur roughly a week after wounding, but can last
upwards of a year, as the tissues within the wound regain their original pre-wound
strength.36,41,42
Perturbations to the highly-systematic wound healing process can occur as a result
of several effectors. These include age, nutrition, illness, smoking, and other
environmental factors. These influences can affect the wound healing process greatly.
For instance, infections can lead to a prolonged inflammatory phase and interference with
epithelialization and collagen deposition. This combined effect can cause lack of wound
closure and possible wound contamination moving forward. Smoking has debilitating

14
effects on the wound healing environment. Nicotine is a vasoconstrictive molecule that
has been shown to decrease proliferation of the critical wound healing cells, macrophages
and fibroblasts.7,36
Often times, the canonical wound healing process, as mentioned previously, refers
to the processes that happen as a result of an acute wound. However, medical conditions,
such as diabetic or pressure ulcers, result in situations of chronic wound healing. Chronic
wound healing differs from that of the acute process in several ways.43,44 First, chronic
wounds often have a large accumulation of inflammatory cells within the wound site.
These cells lead to such negative effects as increased reactive-oxygen species and
increased degradation of extracellular matrix. These combine to generate a state of
habitual inflammation. Secondly, fibroblasts in these wound situations have been shown
to have a lower mitogenic response to growth factors and cytokines. This, in turn,
impedes the formation of granulation tissue and collagen deposition. Keratinocytes are
also affected as a result of a chronic wound state. In diabetic patients, keratinocytes
exhibit impaired migration, which leads to a failure to epithelialize the wounded region.
Lastly, the abundance of inflammatory cells causes a continual state of extracellular
matrix degradation. Collagen deposition and maturation within the remodeling phase of
wound healing is prevented as the inflammatory cells deter the processes from
occurring.44 Together, these effects found in chronic wounds lead to the formation of
poor- or non-healing wounds for their patients as a result of the sustained inflammation
and lack of epithelization of the wound.
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While there are clear differences between acute and chronic wound healing
pathways in humans, there are also major similarities and differences in wound healing
among species. In scientific research, porcine and murine models are used most widely
to relate pre-clinical wound healing studies to humans. Pigs have similar anatomy and
physiology of the skin, blood supply to the skin, and wound healing characteristics when
compared to humans.45 Porcine skin also has similar lipid profiles, epidermal cell
turnover, and carbohydrate metabolism within the epidermis. Due to their highlytranslational ability, pigs are frequently used in pre-clinical studies for wound healing and
plastic surgery. An additional similarity between humans and pigs is the fixed skin.
Fixed skin allows for wound healing by reepithelialization.
Unlike pigs and humans, mice primarily heal through contraction of the skin. To
overcome this disadvantage, researchers have developed splinted-wound models, which
force the mice to heal through granulation and reepithelialization and mimic human
wound healing.46 Murine skin also contains far greater amounts of hair follicles, while
having a thinner epidermal layer when compared to human skin. Even with these few
dissimilarities, mice are still readily used in scientific research due to their abundance,
ability to reproduce data, and low cost – all of which are advantages to using murine
models over pigs. Additionally, and while mice share 95% of the same genes as humans,
mice can easily be genetically modified to study particular disease states, which is highly
attractive for any translational research situation, including wound healing.47
Hemostasis and Coagulation Cascade.
Hemostasis is a crucial first step in wound healing, but it also is a highlyregulated and important homeostatic process within the human body. Hemostasis is
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required for everyday functioning and to prevent blood loss after tissue injury or trauma.
There are three main phases that occur during hemostasis: 1) vascular phase 2) platelet
phase and 3) coagulation cascade.48
The vascular phase of hemostasis begins immediately after injury, which causes
spasm of the smooth muscles in the vessel walls and results in retraction of severed
arteries and vasoconstriction of arteries and veins, thus decreasing the rate of blood
flow.49 This occurs as the pericytes, which are cells that function in the regulation of
blood flow, proliferate and differentiate into endothelial and smooth muscle cells.
Additional factors, such as reflexes initiated by local pain/nervous system receptors, and
chemicals released by endothelial cells and platelets such as von Willibrand’s factor
(vWF), adenosine diphosphate (ADP), thromboxane, and serotonin, can lead to further
vasoconstriction of the blood vessels. This vascular phase can significantly reduce blood
loss for over an hour, which provides time for the formation of the platelet plug and
blood coagulation.50,51
After the vasoconstriction of the blood vessels at the site of injury, the platelet
phase begins and results in ultimate formation of a soft platelet plug.52 In normal
physiological conditions, platelets are small anucluer cells that do not adhere to surfaces
or aggregate with one another.53 However, in the case of injury to a tissue or blood
vessel, platelets are exposed to the subendothelial matrix and various platelet adhesive
proteins and activators. The von Willebrand factor is an abundant platelet adhesion
protein, which interacts with other adhesive proteins, such as collagen.54 The circulating
platelets bind to collagen via the glycoprotein Ia/IIa receptors located on their cell
surface. This adhesion process leads to the activation of the platelets.55 Once activated,
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platelets begin to aggregate at the site of injury through fibrinogen bridges, which link
glycoprotein IIb/IIa receptors located on adjacent platelets, as well as collagen binding.
Additionally and upon activation, platelets can release the contents of their storage
granules, which include ADP, thromboxane A2, and serotonin, which are critical to
platelet aggregation and activation.56 These granules activate additional circulating
platelets, which lead to further aggregation, and activation of coagulation. These
aggregating platelets adhere and create the soft platelet plug at the site of injury.57,58
Although the platelet plug initially stops bleeding, a supplemented and more stable fibrin
clot is required. This fibrin clot is formed during the coagulation cascade.
Simultaneous to the above-mentioned platelet phase, the coagulation cascade
occurs at the wound site (Fig. 4). The coagulation cascade is a complex process that
occurs to stabilize the platelet plug through the generation of a fibrin clot. The
coagulation cascade is comprised of two distinct pathways – the extrinsic and intrinsic
pathways. Both pathways ultimately converge on an identical enzymatic reaction that
leads to formation of the clot.48
The extrinsic, or tissue factor, pathway is activated when the endothelial lining of
the blood vessel becomes damaged.59 This damaging of the vessel wall allows for
collagen and tissue factor (TF) to be exposed and released to the surrounding tissues and
blood. TF is expressed by smooth muscle cells, cells surrounding blood vessels (i.e.
fibroblasts) as well as white blood cells. TF is a cell surface receptor for factor VIIa.
When TF is exposed after injury, the TF/VIIa complex forms. This complex can then
convert factor X to its active form, Xa. After the activation of factor X, both extrinsic
and intrinsic pathways of the coagulation cascade converge at the common pathway –
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activation of X to Xa (Fig. 4). After factor Xa is active, factor Xa, factor V, and calcium
form the tenase complex that is required to convert prothrombin to thrombin. Thrombin
is a serine protease that converts soluble fibrinogen into insoluble strands of fibrin.60
Factor XIIIa catalyzes the formation of covalent bonds between amino acid residues in
fibrin. These covalent bonds increase the stability of the fibrin clot by crosslinking the
fibrin polymers.

Figure 4. The Coagulation Cascade. The intrinsic and extrinsic pathways of the
coagulation cascade. The intrinsic cascade is initiated when contact is made between
blood and exposed negatively-charged surfaces. The extrinsic pathway is initiated upon
vascular injury which leads to exposure of tissue factor, a cell-surface glycoprotein that
binds phospholipids. These two pathways converge at the activation of factor X to Xa –
the common pathway. Active factor Xa activates prothrombin (II) to thrombin (IIa).
Thrombin then converts fibrinogen to fibrin and activates factor XIII to XIIIa. Factor
XIIIa cross-links fibrin polymers creating a final fibrin clot. Roman numerals refer to the
specific coagulation factors. Black arrows indicated the cascade events; red arrows
indicate where the hemostatic agents act within the pathway. Adapted from Monroe et
al.50
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In contrast to the extrinsic pathway, the intrinsic, or contact pathway, is typically
less significant to overall hemostatic balance. The intrinsic pathway is linked to
abnormal physiological states, such as hyperlipidemia and bacterial infections.61-63
Contact activation within the intrinsic pathway can occur through interactions with
phospholipids, lipoprotein particles, and negatively-charged surfaces as well as with
surface proteins and fatty acids on bacteria. This pathway contains more functional
proteins than the extrinsic pathway (Table 1). After activation, the intrinsic pathway is
initiated with the formation of a complex of high-molecular-weight kininogen (HMWK),
prekallikrein, and factor XII (Fig. 4). The formation of this complex converts both
prekallikrein to kallikrein and XII to XIIa – their active forms. Factor XIIa goes on to
convert XI into XIa, and subsequently XIa activates IX.48 Factor IXa, along with its cofactor VIIIa and calcium, forms a complex with their combined substrate, factor X.
Factor X is converted to Xa, and the common pathway of the coagulation cascade is
activated with the ultimate arrival at a fibrin clot formed through conversion of
fibrinogen to fibrin by thrombin.
However, thrombin has other functions that are vital for maintaining hemostasis.
Additionally, thrombin acts to convert factor XI to XIa, VIII to VIIIa, and V to Va.
These conversions are considered positive feedback mechanisms by which amplification
of the coagulation cascade can occur. Thrombin can also activate factor XIII to XIIIa. In
addition to its activity in the coagulation cascade, thrombin promotes platelet activation
and aggregation.64
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Factor/Name
Factor I (fibrinogen)
Factor II (prothrombin)
Factor III (tissue factor, TF)
Factor IV (calcium)
Factor V (Proaccelerin)
Factor VI (Accelerin, Va)
Factor VII (Proconvertin)
Factor VIII (Antihemophilic globulin)
Factor IX (Christmas factor)
Factor X (Stuart-Prower factor)
Factor XI (Plasma thromboplastin
antecedent)
Factor XII (Hageman/contact factor)

Function(s)
Converted to fibrin by Factor IIa
(thrombin). Creates fibrin clot.
Converted to thrombin by Factor X. Factor
IIa converts fibrinogen to fibrin.
Initiates the extrinsic pathway. Interacts
with Factor VII.
Is required for activation of Factors II, VII,
IX, X, and XIII.
Essential for activation of thrombin.
Also known as Factor Va
Binds to TF and is essential for the
activation of Factor X.
Important to the activation of Factor X.
Essential to the activation of Factor X and
the common pathway.
Converts prothrombin to thrombin.
Activates Factor IX in intrinsic pathway.

Essential to the intrinsic pathway and the
activation of Factor XI.
Factor XIII (fibrin-stabilizing factor)
Aids in the final fibrin clot formation
through stabilization of fibrin fibers.
Kallikrein
Essential for Factor XII activation,
necessary in Factor XIIa activation of XI.
Table 1. Factors of the Coagulation Cascade. Adapted from Moss et al.65
The hemostatic pathway is a critical physiological pathway; however, it is in a
constant state of homeostasis. As the fibrin clot is being formed throughout the
coagulation cascade, the fibrinolytic system is already beginning to disrupt it.51,66 The
fibrinolytic system functions to dissolve blood clots in healthy blood vessels (i.e. prevent
thrombosis) and during the wound healing process. Plasmin is the key effector in this
system. Plasmin is a zymogen that is generated from its inactive precursor, plasminogen.
Plasminogen is converted into plasmin by two proteases – tissue-type plasminogen
activator (tPA) and urokinase-type plasminogen activator (uPA).67 For balance, these
PAs are regulated by plasminogen activator inhibitors. However, after plasminogen is
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activated to plasmin, it cleaves fibrin at specific lysine and arginine residues, which
ultimately results in dissolution of the clots.
Working alongside these proteases is thrombin-activated inhibitor of fibrinolysis
(TAFI). TAFI is also a zymogen that can be activated by either plasmin or thrombin.
While the fibrin clot is being degraded, C-terminal lysine residues are exposed and can
enhance activation of plasmin and further fibrin degradation. TAFI, however, removes
these lysine residues from fibrin fibers and inhibits any further plasmin(ogen) activation.
Taken together, the effectiveness and balance of the hemostasis depends on both the
procoagulation reactions of the coagulation cascade as well as the clot-dissolving process
in the fibrinolytic system.68,69
The fibrin clot functions in a variety of important physiological processes
throughout the body.16 The most known function of fibrin is within the coagulation
cascade. Upon injury, fibrin and its constituents are formed, processed, and degraded in a
highly-defined pathway. Due to the influence of the coagulation cascade and hemostasis
on wound healing, fibrin has been shown to play an important role in the healing phases.
Hemostasis is the first phase in wound healing. The network of insoluble fibrin fibers
that is created as a result of the coagulation cascade stabilizes the platelet plug.22 This
fibrinous matrix acts as a scaffold during wound healing for a plethora of cell types.
Because of the integrin and non-integrin bindings site of fibrin, cells such as endothelial
cells, smooth muscle cells, and fibroblasts can easily attach and migrate to the fibrin
matrix to initiate the wound-healing response.17,18
After these initial contacts, fibrin can also bind monocytes and leukocytes, which
are two prominent cell types for the secondary, inflammation phase of wound healing.70,71
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These cells eliminate debris and bacteria from the wound site.72,73 In line with the wound
healing phases, fibrin also serves as a provisional matrix for endothelial cells and
fibroblasts. The endothelial cells, upon stimulation by growth factors, proliferate and
migrate into the wound site. There, they begin to generate new vasculature.74,75
Following the proliferative phase of wound healing, remodeling of the wound area
occurs. Fibroblasts initially use the fibrin matrix as a scaffold for migration and
proliferation. Once the fibroblasts have entered the wound, they begin to create collagen
as well as other extracellular matrix proteins to regenerate the tissue.76,77 At each step
along the wound healing process, fibrin has been shown to be an integral factor. Fibrin
has critical roles in hemostasis, inflammation, and revascularization due to its inherent
binding sites for cellular receptors, integrins, and clotting and growth factors.17-19
Although the hemostatic and wound healing phases are sequential and regulated,
medical and clinical indications can manifest causing perturbations to this normallybalanced pathway. Surgical or accidental trauma as well as genetic predispositions can
alter hemostasis through abnormal (or lack of) formation of the platelet plug or fibrin
clot.
To combat these clinical situations of excessive or abnormal bleeding, the medical
field has several hemostatic therapies at its disposal (Table 2).78 These include
mechanical, energy-based, and chemical methods to control bleeding – each with their
own specific indications and impact on coagulation (Fig. 4).65 Mechanical methods, such
as direct pressure, gauze, sponges, and sutures/staples are often used. These measures
rely on the physical strength and barrier formation to prevent further blood loss. Thermal
and energy-based hemostatic methods (e.g. electrosurgery, ultrasound, and lasers) have
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been employed for their use in achieving hemostasis. Electrosurgery utilizes highfrequency alternating currents to cut, coagulate, and vaporize tissues; while ultrasound
devices covert electrical energy into mechanical energy that can seal blood vessels.
Additionally, lasers use highly concentrated light energy to cauterize bleeding tissues.
The thermal and energy-based hemostatic techniques must, however, be used by properly
trained medical professionals due to their complex equipment and functionalities.79,80
Mechanical
Thermal & Energy-based

-Direct pressure
-Gauze, sponges
-Sutures, staples
-Electrosurgery
-Ultrasound
-Laser

Chemical
-Pharmacological

-Epinephrine
-Vitamin K, Vitamin K analogs
-Protamine
-Desmopressin
-Lysine analogs

-Hemostatic Agents

-Mechanical
 Collagen
 Gelatin
 Cellulose
-Active (Thrombin)
-Sealants
 Fibrin
 Polyethylene glycol (PEG)
 Albumin, glutaraldehyde

Table 2. Methods for Achieving Hemostasis. Adapted from Samudrala et al.78
The final means for (re-)establishing hemostasis is through the use of chemical
methods. Both pharmacological and hemostatic products are used in cases where the
mechanical and thermal methods are impractical or otherwise contraindicated, such as
instances of bleeding over multiple vessels or areas of the body. Pharmacological
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treatments, as named in Table 2, are primarily used to improve final fibrin clot formation
through either preventing anticoagulation or increasing the platelet aggregation to the
bleed site. Mechanical (or passive) hemostatic agents stop the flow of blood by either
providing a scaffold for the rapid formation of a native clot, or by physically acting as a
barrier to stop the bleeding. In contrast, active hemostatic agents, such as thrombin
products and fibrin sealants act to recapitulate the endogenous coagulation cascade and
fibrin clot formation.80,81
Fibrin and Fibrin Sealants.
Fibrinogen is cleaved by thrombin to generate a fibrin clot during the final step of
the coagulation cascade (Fig. 4). This single step within hemostasis has a far greater
reach over the physiological processes within the human body. Not only is fibrin critical
to clot formation during hemostasis, but fibrin is an important factor in wound healing,
inflammation, angiogenesis, and neoplasia.16 Fibrinogen is a 340 kilodalton (kD)
glycoprotein that consists of a dimeric structure composed of 2Aα, 2Bβ, and 2γ chains.
The Bβ and γ chains make up the D-region of fibrinogen and create an alpha-helical
structure, while the Aα chains of the E-region are globular (Fig. 5).82
Thrombin is a serine protease of the trypsin family of proteins that is generated
from its zymogen, prothrombin. During the coagulation cascade, prothrombin is cleaved
into thrombin by factors Xa and Va. Cleavage of prothrombin into thrombin occurs with
two sites and can be generated through two possible pathways (Fig. 5). Initial cleavage
yields N-terminal fragments 1 and 2 (F1.2) and the zymogen, prethrombin, which is
further cleaved to yield the disulfide linked thrombin (left pathway of Fig. 5A).
Alternatively, cleavage in the opposite order generates an immediate, meizothrombin,
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prior to processing into the active thrombin (right pathway of Fig. 5A). Thrombin, in its
active form of α-thrombin, is a 36 kD protein. Thrombin is known to act as a
procoagulant and anticoagulant enzyme with the human body. Thrombin elicits a
response during the coagulation cascade to form a fibrin clot and also activates platelet
activation during the earlier stages of hemostasis.83 For anticoagulation, thrombin has
been shown to interact with thrombomodulin, which is a required molecule for the
activation of protein C – an inactivator of factors Va and VIIIa leading to down
regulation of thrombin generation.

Figure 5. Structures of Thrombin and Fibrinogen. A) α-thrombin is generated by the
autocatalytic and factor Xa cleavage of prothrombin. α-thrombin, the active form of
thrombin, is covalently linked through disulfide bridges. B) Fibrinogen is dimeric
glycoprotein composed of 2Aα, 2Bβ, and 2γ chains. Fp: Fibrinopeptides. Adapted from
Wood et al and Undas et al.82,84
When fibrin formation occurs, fibrinogen is converted to fibrin by thrombin (Fig.
6). Thrombin cleaves fibrinopeptides (Fp) A and B from the Aα and Bβ chains in
fibrinogen. The release of these peptides contributes to the lateral aggregation of the
initial fibrin clot. Cross-linking and expansion of the fibrin clot occur after the inclusion
of factor XIII. Factor XIII allows for the crosslinks of the γ-chains and overall expansion
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of the final, stabilized fibrin clot. This overall fibrin clot structure is dependent on many
variables, including pH, salt concentration, thrombin concentration, factor XIII
concentration, and fibrinogen cross-linking. pH changes can affect the fibrin fiber
thickness, with more basic pH environments leading to thinner fibers. Increased salt and
thrombin concentrations increase clotting rate, which leads to thinner fibrin fibers as well.
Factor XIII and fibrinogen alterations can cause changes in branching and polymerization
in the final fibrin clot. Each of these factors may lead to variations of the fibrin clot and
can impact the function of the clot itself.82,85
The fibrin clot also possesses unique biomechanical and viscoelastic properties.
Fibrin clots have the tensile strength to stop bleeding and hold tissues together; while also
having burst pressure to withstand the forces of arterial blood flow. Fibrin is elastic and
viscous as well. It can deform and withstand shear forces within the body while
remaining fluid due to its high elasticity.85 Fibrin clots also possess unique structural
qualities as well. Fibrin contains a structure encompassing a spectrum of porous void
spaces – from a few nanometers to 50 µm.86 This porosity is crucial to fibrin functioning
and has a direct impact on cell migration on fibrin, air/fluid transfer through the clot, and
overall permeability.
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Figure 6. Fibrin Clot Formation. Schematic of fibrin clot formation. Fibrin
polymerization is initiated by the action of thrombin, which cleaves the fibrinopeptides
from the middle of fibrinogen to produce fibrin. These initial oligomers lengthen with
the additional monomers to make protofibrils, which aggregate to form fibrin fibers.
These fibers branch into a three-dimensional fibrin network, which is finally stabilized by
the formation of covalent bonds introduced by the plasma transglutaminase, factor XIII.
Adapted from Undas et al.82
Due to the impact of fibrin on multiple human systems, its biocompatibility, and
advantageous biomechanical attributes, fibrin has been well-characterized and used in the
medical field for a variety of applications for over a hundred years.87 Fibrin sealants are
two-component medical devices that contain fibrinogen and thrombin. These agents are
combined and generate a fibrin clot. Variations of fibrin sealants exist as well –
including alterations to the formulation (i.e. increasing or decreasing thrombin
concentrations, use of human, bovine, or synthetic proteins), addition of constituents (i.e.
other hemostatic agents), and freeze-drying.88
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Each preparation of a fibrin sealant is created for a particular use. Fibrin sealants
can be used as hemostatic agents, sealants, or adhesives.89 Hemostatic agents (e.g.
hemostats) are the canonical use of a fibrin sealant, whereby their use is dependent on a
bleed and fibrin to generate a clot. A sealant creates a barrier between surfaces to prevent
leakage of liquids and gases. Lastly, fibrin sealants functioning as adhesives are used for
ability to glue structures together. With each preparation, the indications for a particular
fibrin sealant become apparent. Hemostats can be used in most surgical situations where
bleeding occurs. Sealants can be used as wound therapies and to repair tissue
anastomoses, while adhesives are employed for use in reconstructive surgeries, such as
burn and skin grafts.87,90,91
While the aforementioned practices of fibrin sealants are ever-abundant in the
medical field, newer and more innovative uses for fibrin sealants are being studied. In
recent years, fibrin sealants have been altered to serve as a template for cellular
migration. Their matrix interactions with various cell types, such as those in wound
healing, allows for a candidate scaffold for wound repair. Additionally, fibrin sealants
have been widely studied for their use as a delivery system. Pharmaceutical drugs,
growth factors and cytokines as well as cells have been incorporated into fibrin matrices
for use in a spectrum of medical applications.92-94
Lastly, fibrin sealants have gained appeal in the field of tissue engineering. Due to
their cellular and protein interactions, fibrin sealants are considered active cellular
matrices. Along with their mechanical and biochemical properties, fibrin sealants are
attractive candidates for further applications in tissue engineering and as matrices for
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cellular differentiation. By combining fibrin with other stimulating factors, these sealants
could be used as highly-customizable scaffolds.90,92
Wound Therapy.
To promote proper wound healing and prevent the possible risks caused by
inadequate healing, a variety of wound closure treatments and dressings are available for
clinicians (Table 3).95 These wound therapies range from the components of the therapy
to the mechanism by which the therapy acts to close the wound. Traditional wound
therapies include gauze, sutures, staples, and wound-closure strips. These therapies have
been used for many decades and rely on their mechanical strength to hold and seal the
wounds. While reliable in most skin wounds, the use of these agents is often limited to
their reach and placement on the wound. Additionally, these traditional therapies can
often lead to dehiscence and improper sealing of the wound.1,2
There are two main classes of sealants used for wound healing: biologic (e.g.
albumin, collagen, and fibrin sealants) and synthetic (e.g. hydrogels, cyanoacrylate, and
polymers). The biologically-derived sealants products have inherent hemostatic
properties to decrease blood flow and allow for adherence to the tissue. Synthetic sealants
elicit tissue adherence within minutes without the use of sutures or staples. These
sealants are also biodegradable and slough off or become resorbed by the body once the
underlying wound site has fully healed. These materials chemically bind to tissue,
provide immediate sealing of tissues with significant tensile strengths and without the
risk of immunogenicity.2,4
Polymers have also been used to synthesize gauze, foams, and other dressings.
Polyurethane dressings are used in the treatment of acute and chronic wounds. These
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wound dressings are permeable to both gases and fluids, including wounds with
moderate-to-heavy exudates. Moreover, polyurethane dressings are biocompatible, have
relatively low toxicity, and can be fashioned to a specific pore size matrix. These
specific matrices can be utilized in different therapies and can enhance reepithelialization
while providing mechanical stability to the wound site. A common disadvantage to these
polymer dressings is their limited biodegradability. These dressings must be changed or
removed periodically during the wound treatment process, which ultimately can lead to
delayed healing.96
Physical and energy-based processes have also been coupled to wound closure
methods to aid in wound healing. One of which is negative-pressure wound therapy
(NPWT), which utilizes a subatmospheric vacuum system to improve wound healing.
This technique is often used in hard-to-close acute and chronic wounds because of its
ability to seal the wound edges and remove excess exudate from the site of injury.
NPWT involves the use of polyurethane foam or gauze to cover the wound site and is
ever-growing in popularity for patients with skin grafts, dehisced surgical wounds, and
pressure ulcers. NPWT-treated wounds often require debridement of the polyurethane
wound dressings after several days of treatment due to the tissue ingrowth. This leads to
pain, discomfort, and re-wounding of the tissue.2,95
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Class/Type
Gauze

Characteristics
Cotton fiber; inexpensive material; requires
frequent changes on the wound
Sutures
Absorbable or non-absorbable; variable
tensile strength; may enable infections
Staples
Stainless steel or titanium based; technique
needed for application
Tapes/Films
Cost-effective; not suitable for wounds
with heavy exudates
Hydrogels
Water- or glycerin-based gels; nonadherent to wound
Hydrocolloids
Pectin- or gelatin-based gels; adherent and
may cause damage to skin
Foams
Polyurethane based; can absorb moderate
exudate
Alginates
Suitable for wounds with heavy exudate;
some hemostatic activity
Sealants
Human-, animal-, or synthetic based
platforms; ability to seal wound; protect
wound from infection
Silver Dressings
Contain broad-spectrum antimicrobial
activity; should be used for infected
wounds
Vacuum
Removes exudate from wounds;
mechanical seals wounds; increasing
perfusion
Table 3. Classification of Wound Therapies. Adapted from Janis et al.6
Ultrasonic and radiofrequency are two energy-based therapies that have gained
recognition for use in wound healing. Ultrasonic wound therapy uses ultrasonic
frequencies to fuse and seal tissues together. Similarly, radiofrequency techniques, or
electrosurgery, can generate high temperatures from radio waves to be used to cauterize
the wounded tissues. These energy-based techniques have become more popular over the
traditional sutures and staples because of their ability to create a leak-proof seal in the
wound. The requirement of specialized tools and training to use such devices, though, is
a larger disadvantage to their use.2
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While all available wound therapies have their respective advantages and
disadvantages for use in clinical situations, the ideal wound therapy or dressing still
eludes the scientific community. This optimal wound therapy has been postulated to
require the following attributes10,95:


Ease of application



Reduce heal time



Biocompatible to tissue



Biodegradable



High mechanical strength and elasticity



Fluid and gas permeability



Non-toxic and non-antigenic



Affordable and long shelf life



Resistant to bacterial/microbial infection

Researchers in the later part of the 20th century began generating more modern wound
therapies to try and meet these requirements and provide superior wound healing
therapies for patients worldwide. These include the use of stem cell therapy, gene
therapy, and tissue engineering. Stem cells have been favored as they are critical to
tissue regeneration and wound healing in the body. Stems cells recapitulate wound
regeneration and provide daughter cells that can replenish the lost or damaged tissues
through cellular differentiation.14
Gene therapy has been a novel wound therapy as it allows for the implantation of
genes/transgenes into recipient cells. These genes, often encoding growth factors or
cytokines, can be used to promote wound healing through the added recruitment of cells
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and other tissue factors. For example, virally-transferred epidermal growth factor (EGF)
could be implanted at a wound site for the downstream effect of leading to the
proliferation of epidermal and mesenchymal cells; whereas platelet-derived growth factor
(PDGF) would allow for the chemotactic response and matrix production of macrophages
and fibroblasts, respectively. Downsides to this potential therapy are immunological or
toxic side effects as well as the risk of tumor development.97 Additionally, these
therapies apply one gene encoding one cytokine or growth factor, with limited effects. A
typical wound environment has dozens of factors present. While stem cells and gene
therapies are promising, very few have reached clinical trials.
Lastly, tissue engineering has been at the forefront of recent studies in wound
healing research. Tissue engineering aims to mimic the structural and cellular elements
of a tissue to promote the repair and regeneration of that tissue, which is appealing for a
wound healing situation. Current tissue engineering scaffolds vary on the test material
and range from collagen, fibrin, and hyaluronic acid to acellular matrix and
biodegradable polymers.13,14
Tissue Engineering.
Tissue engineering has gained interest over the past twenty years for its versatile
role in many clinical situations, including wound healing, due to the highly-customizable
ability of tissue-engineered scaffolds. Tissue engineering’s goal is to mimic tissue
regeneration by creating suitable cellular microenvironments. The scaffolds restore the
cellular microstructures and mechanical properties of the tissues by possessing critical
attributes, including porosity, biocompatibility, and biomechanical strength – making
them ideal therapies for medical intervention.10,14
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The porosity of the scaffolds is one of the most important attributes to its success.
The pore sizes of a scaffold can be manipulated for a given clinical indication. Pore sizes
affect different cell types and cellular processes depending on their sizes (Table 4).15,98,99
Due to the ability of tissue-engineered-scaffolds to be customized, researchers may alter
their scaffold’s pores to fit and treat a particular problem.
Cellular Process
Angiogenesis
Adipogenesis

Cell Type/Model Used
Pore size (µm)
In vivo rat implantation
160-270
Bone marrow stem cells,
70-110
adipose-derived stem cells
Cellular infiltration
Dermal fibroblasts
100
Chondrogenesis
Porcine chondrocytes,
70-120, 200-500
rabbit mesenchymal stem
cells
Osteogenesis
In vivo mouse implantation
150-400
Proliferation
Human fibroblasts
100-250
Skin regeneration
Guinea pig dermal and
20-125
epidermal cells
Smooth muscle cell
Canine bone marrow stem
50-200
differentiation
cells
Table 4. Pore Sizes Required for Various Cellular Processes. Pore sizes required for
various cellular processes. Pore sizes (µm) detail the approximate range required for a
scaffold’s structure to support the cellular processes listed. Adapted from Loh et al.15
The porosity of a scaffold also affects its permeability. Permeability of these
scaffolds plays a significant function in its overall effectiveness. The scaffolds must be
able to allow for cellular migration and infiltration, but also for nutrient, waste, and fluid
transport in and out of the structure. Additionally, the scaffolds must possess
biomechanical strengths to support tissue growth and movement.99
Tissue-engineered scaffolds can come in all shapes and sizes and can be created
from a variety of substrates to accomplish the goals of tissue regeneration.
Biocompatibility and biomechanical strength go hand-in-hand with the chosen substrate
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for the particular scaffold. The ideal matrix is biocompatible, promotes regeneration and
cellular integration, and fully incorporates into the tissue.
Collagen is often used for tissue engineering and wound healing situations. It is
biocompatible, non-immunogenic, and is readily absorbed into the tissue site. Due to its
similar structural properties to extracellular matrix proteins, collagen-based scaffolds can
be used in a variety of regenerative applications, including bone, skin, and wound
repair.100 Another often-used scaffold is hyaluronic acid. This polysaccharide is present
in connective tissues within the body and, while biocompatible, is readily digested.
Because of its impact in connective tissues, hyaluronic acid scaffolds are sought after for
use in cartilaginous repair and wound healing.101
Chitosan is an aminopolysaccharide found in the exoskeleton of insects, shellfish,
and fungi.102 Chitosan, while porous, biocompatible, and biodegradable, is often
combined, in practice, with hyaluronic acid and collagen-based scaffolds for use in a
variety of applications.
Fibrin, often utilized as a surgical sealant, is a versatile scaffold in tissue
engineering.103 Fibrin-based scaffolds have excellent biocompatibility and have been
fabricated with additional cells, growth factors, and pharmaceutical drugs to improve
tissue regeneration.
Acellular matrices are derived from animal tissue for which the living cells have
been removed. This matrix is appealing for tissue engineering because of its several
advantages. These matrices are biocompatible and biodegradable, but are also
morphologically identical to the tissue structures. This allows for improved cellular
migration and infiltration. Additionally, acellular matrices have similar biomechanical
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strengths to the surrounding tissues.104 Due to these attributes of decellularized matrices,
their use in organ transplant has been a recent hub of tissue engineering research.
Acellular matrices have been employed in many clinical indications, including as
artificial skin scaffolds as well as human tracheal matrices for use as bronchial
transplants.105
While natural and biological materials have the added attributes of
biocompatibility and similar structural characteristics to the native tissues, synthetic
polymers have gained appeal in recent years for their use in tissue engineering. These
scaffolds can be generated from many polymers, including polyesters, polylactic acid,
polyglycolide, poly(lactic-co-glycolic acid), and others.106 These polymers are
biodegradable and have additional advantages as well. The polymers have added
biomechanical strength over natural materials, can be processed to meet exact porosity
requirements, and have controlled degradation rates over time. As long as the
degradation byproducts are non-toxic, these polymeric scaffolds can be fabricated to treat
a wide array of tissue engineering-related issues.
Because of the capacity to influence all properties of the scaffolds, researchers
have also manipulated the above materials through addition of cells, growth factors, and
other molecules to aid in improved tissue regeneration.107 Stem cells, for instance, have
been implanted in these matrices to allow for improved healing and growth of tissues.
The tissue engineering field is continuing to grow in hopes of finding optimal scaffolds
for tissue regeneration, wound healing, bone growth, and other medical issues.
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ARTISS Fibrin Sealant.23
ARTISS is a fibrin sealant marketed by Baxter Healthcare Corporation. ARTISS
was first approved by the FDA for use in the United States in 2008. ARTISS is a fibrin
sealant preparation made from pooled human plasma, where both components
(fibrinogen and thrombin) are formulated as two sterile, deep-frozen solutions. These
solutions are presented in two, separate pre-loaded chambers of a single device that mixes
those two components at the syringe tip (Fig. 7). ARTISS is generated in a deep-frozen,
vapor-heated and solvent detergent-treated state that has a two-week shelf life once
thawed at room temperature.
The two components of ARTISS fibrin sealant are denoted as the sealer protein
solution (i.e. fibrinogen) and thrombin solution. The sealer protein contains active
ingredients as listed in Table 5. The sealer solution contains addition excipients (per 1
mL): human serum albumin (10-20 mg), histidine (10-25 mg), sodium citrate (4.8-9.7
mg), Polysorbate 80 (0.6-1.9 mg), nicotinamide (3-9 mg), and water for injection q.s. to 1
mL. Of these added excipients, human serum albumin acts as a protein stabilizer and
buffer to pH. Polysorbate 80 is an emulsifier, while histidine, sodium citrate, and
nicotinamide are used for buffering and pH agents. The thrombin solution contains two
active ingredients as listed in Table 6. The thrombin solution contains the addition
excipients (per 1 mL): human serum albumin (45-55 mg; protein stabilizer) and sodium
chloride (3.5-5.5 mg, buffer).
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Figure 7. ARTISS Fibrin Sealant. Photograph of a pre-filled dual-component syringe
of a 10 mL preparation of ARTISS fibrin sealant (Baxter Healthcare Corporation).
Source of image: Baxter Healthcare Corporation.23
Active Ingredient

Quantity/Amount

Fibrinogen

72-110 mg

Factor XIII

1.2-10 IU

Synthetic Aprotinin

2250-3750 KIU

Table 5. Sealer Protein Active Ingredients. KIU: Kallidinogenase Inactivator Unit.
Active Ingredient

Quantity/Amount

Thrombin

3.2-5 IU

Calcium Chloride

36-44 µmol

Table 6. Thrombin Solution Active Ingredients.
The two-component system, when mixed, acts to mimic the final step of the
coagulation cascade – formation of a fibrin clot. Thrombin converts fibrinogen to fibrin.
This process is repeated as the fibrin fibers begin to polymerize. The polymerized
network of fibrin fibers is crosslinked by the native (or added) factor XIII to form the
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final fibrin clot (Fig. 4). This clotting process, however, takes approximately one minute
to begin and two hours to generate a full-strength clot due to the low thrombin
concentration within the thrombin solution.
Because of this slower set time compared to other fibrin sealants, ARTISS is
indicated for use as tissue glue to adhere/seal subcutaneous tissue in plastic,
reconstructive and burn surgery, as replacements or adjuncts to sutures or staples.
Additionally, ARTISS is indicated as adjunct to hemostasis on subcutaneous tissue
surfaces. ARTISS is contraindicated for use in replacing skin sutures intended to close
surgical wounds. ARTISS, by itself, should not be used for the treatment of massive
arterial or venous bleeding, and the sealant can never be applied intravascularly for risk
of thromboembolism.
ARTISS has been well-studied and was investigated in human clinical trials,
including use for the fixation of skin grafts in burn patients and for the adherence of skin
flaps in facial rhytidectomy surgeries. In the burn patients, ARTISS proved to be noninferior to staples with respect to wound closure at 28 days after wounding using a onesided 97.5% confidence interval on the difference in the proportion of test sites
successfully treated (ARTISS 43.3% of wounds closed at Day 28 compared to 37.0% of
wounds using staples). Additionally, a facial rhytidectomy trial was performed to
investigate the adherence of skin flaps using ARTISS. A standardized drain was placed
on the face of each patient where the skin flap was placed to compare adherence. At 24
hours post-operation, ARTISS-treated skin flaps had a significantly lower volume of
drainage, correlating to better overall adherence (p<0.0001). ARTISS-treated skin flaps
also resulted in significantly less incidence of hematoma/seroma when compared to the
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standard of care (p<0.05). Depending on the indication, ARTISS also comes with
different application equipment. Cannulas are often employed for use in small wounds or
for the edges of skin grafts. A spray set is also offered. The spray set is highly
recommended for use in large surface areas requiring tissue adherence.
Foams: Properties and Uses.
Foams are universal in everyday life – from soap bubbles, detergents, packaging,
and foods and beverages to firefighting and biomedical foams.108 Foams are substances
generated by trapping gas in either liquid or solid, resulting in an aqueous or dry foam,
respectively. Foams can additionally be characterized by their pore structure. Open-cell
foams have interconnected pores that allow for rapid movement of gas and liquids across
the foam. Closed-cell foams, on the other hand, trap gas within individual pockets and
thereby restrict the flow of gas and liquids. The more commonly studied foams are the
ones generated from liquid and gas – aqueous foams.109
Aqueous foams, in general, may be made through several techniques, including 1)
blowing gas through a small hole/nozzle into a liquid, 2) sparging, or blowing gas into a
liquid through a porous plug, 3) nucleation of gas bubbles in a supersaturated liquid, and
4) mechanically shaking or beating the liquid.108 The formation and breakdown of foams
occurs in phases as well (Fig. 8). First, bubbles are formed and grow through the
aqueous foam (Fig. 8A). As the bubbles grow, they begin to cream and deform onto one
another generating a distinct polyhedral shape. Following the creaming process, drainage
occurs once the bubbles are more tightly packed. Drainage refers to the liquid passing
through the intricacies between bubbles. As the bubbles begin to form distinct borders
with one another, the bubbles coarsen, or form larger bubbles, when the borders between
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the bubbles merge. Lastly, as the bubbles become larger and larger, the final process in
the lifecycle of an aqueous foam is rupture (Fig. 8E). The borders between bubbles
collapse leading to the dissolution of the foam.108,110,111
Several factors are needed to generate an aqueous foam. As mentioned, this type
of foam is created when a gas is mixed into a liquid. However, often times a surfactant is
required to generated and stabilize the foam. A surfactant, or surface active compound, is
typically concentrated on the surface of foams and reduces the surface tension/energy
associated with the foam surfaces. Additionally, a surfactant stabilizes an aqueous form
from rupture.108,112 Surfactants, such as emulsifiers, detergents, and wetting agents, are
amphiphilic molecules – a molecule that contains both a hydrophobic and hydrophilic
end. These molecules act to lower the interfacial tension between the bubbles in the
foam. The surfactants stabilize the bubbles through the Marangoni Effect, which occurs
when bubbles coarsen and increase their local surface area between the lamellae.108,110
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Figure 8. Foam Formation and Lifecycle. A) Foam formation begins as smaller
bubbles dissolve, while larger ones grow in size by diffusion of gas. B) As bubbles begin
to cream, segregation occurs between the foam layer and liquid layer. C) Next, bubbles
deform one another leading to the polyhedral foam structure of the bubbles. D)
Coarsening occurs as liquid drains among bubbles and bubbles become larger. E)
Finally, the lamellae between bubbles begin to rupture yielding only few remaining, large
bubbles. Adapted from Weaire et al.108
The versatility of foams – both liquid and solid foams – has never been more
ubiquitous. Foams are found on a daily basis and can be generated from many different
organic and inorganic materials. Even animals, insects, and plants have been studied for
their ability to create foam structures.108 The spittlebug, for instance, produces a bubbled
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spit to protect its body from the sun and predators. The Cork Oak tree contains highlyelongated cells, which generates the porous cork material that is a familiar commodity.
More recently, biomedical foams have become widely used in various applications.
These biocompatible and biodegradable foams also have substantial mechanical
properties. Additionally, biomedical foams can be manipulated, designed, and
manufactured to exact specifications for use in medical situations. Because of this
appealing quality to scientific researchers, foams have been used in: porous biomedical
devices, in vitro scaffolds, in vivo tissue regeneration, and as drug-delivery vehicles.113
Biomedical foams have evolved over the years. Initially these foams were created
from metals – for their longevity and high mechanical strengths. In recent years, foams
have been more commonly generated from ceramics, such as glass and carbon, to
inorganic (polyesters) and organic (lipids, polysaccharides) polymers. Lastly, composite
foams have been used to overcome the often problematic issue on incompatibility
between tissue/recipient and the foam. Composites, such as collagen and fibrin, are
naturally-occurring and can provide an excellent balance between mechanical strength
and biocompatibility.113
Fibrin Foam.
Fibrin foam is a novel biopolymer generated from the aeration of the fibrin
sealant, ARTISS. The processes for making the foam and the devices are both patented
and owned by Baxter Healthcare Corporation.24-27 Several embodiments for creating a
foam from fibrinogen and thrombin are detailed in their patents, such as dual-chambered
syringes and other mixing apparatuses. However, one such embodiment (Fig. 9A) was
pursued in preliminary studies. This process for generating fibrin foam has been
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previously described by Baxter researchers. In short, two syringes with male 6% luers
are filled using constituents from ARTISS. One syringe contains thrombin (with or
without air) while the other syringe contains fibrinogen (with or without air). At least
one syringe must contain air to allow for foam formation. Between the syringes is a
patented mixing device, which consists of two female luer locks and a porous mixing
disc. The mixing device is known as Mix-F (Fig. 9B), while the porous disc is called
Vyon-F. The porous disc is produced by Porvair (UK) and is a sintered porous
polyethylene disc. The disc (Ø3.8 x 1.5 mm) has a porosity of 38.9% and an average
pore size distribution of 60 µm (Fig. 9C).28

Figure 9. Preparation Apparatus and Device for Generation of Fibrin Foam.
Preparation of fibrin foam using ARTISS fibrin sealant. A) Dual syringes containing
either thrombin (+ air) or fibrinogen (+ air) are mixed through a patented mixing device,
Mix-F (B). C) CAD model of the Vyon-F mixing disc housed inside Mix-F device.
Images obtained from Baxter patents and internal documentation.24-28
To generate the foam, the fibrin components are repetitively passed through the
mixing device, from one syringe to another. Thus, this aeration and manual mixing
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through the Mix-F device allows for a homogenous combination of fibrinogen and
thrombin constituents into the foamed matrix. While the patents detail a wide array of
potential uses and treatments of fibrin foam, only limited characterization has been
performed on the mixing device and the foam itself. The foam, when compared to
ARTISS, has similar degradation and alpha-chain crosslinking formation. However,
fibrin foam has greater viscosity, can polymerize in a temperature-independent manner,
and can be applied to both vertical and inverted surfaces without dripping. Also, the
mixing process to generate the foam causes the fibrin structure to be an open, porous clot
compared to the dense, closed structure of ARTISS (Fig. 10A, 10B).
However, this internal research was only performed in initial stages of conceptual
design. Due to its porous structure and fibrin matrix, fibrin foam has the potential to be
an applicable wound therapy in specific surgical settings. The foam has a clot structure
that could allow for cellular migration and infiltration that would promote improved
wound healing. Moreover, the foam’s advantage of increased viscosity could permit
treatment of hard-to-treat wounds, such as diabetic foot ulcers or bed sores, which must
be treated from vertical or inverted angles. These attributes would provide multiple
advantages over current wound therapies. And it is with this research, that I aimed to
optimize the fibrin foam preparation while also characterizing the foam and assessing its
untapped potential as an innovative wound therapy.
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Figure 10. Macroscopic and Microscopic Images of ARTISS and Fibrin Foam. A)
ARTISS fibrin sealant (left) and fibrin foam (right) gross images after being manually
prepared. B) SEM images of ARTISS (left) and fibrin foam (right). Scale bars for SEM
images: 50 µm.
Wound Care Market.
The wound care market is ever-expanding and continues to see growth in revenue
and scientific research. The global wound care market was estimated at $15.8 billion in
2013.2 It is expected to reach $22.1 billion by later this year.4 The key drivers of this rise
are: aging population, obesity, and incidence of diabetes, which are all escalating around
the world. Additionally, factors such as burns and surgical-related wounds demand the
use of wound care products, thereby increasing revenue in this market. The wound care
market involves many types of treatments and dressings as previously described. Each of
the key classes of wound healing treatments has a different outlook in the current and
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future markets. The traditional wound dressings segment continues to dominate the total
wound care market and was at $3.3 billion in 2013.1 Low cost, local availability, and
ease of use and maintenance are the primary reasons for gauze and bandages dominating
this segment, especially in the Asia-Pacific and BRIC (Brazil, Russia, India, and China)
countries. Wet dressings are perceived to be best suited for quicker wound healing at an
affordable price. The market in hospital care has been driven by increased sales volume.
It is expected to generate $2.9 billion in revenue by 2018.2,5 However, traditional
(sutures or staples) and wet dressings (dry-to-wet gauze) come with several consequences
that often impair wound healing, such as risk of evisceration and infection. These wound
care markets are in need of products that can minimize these risks and improve sealing of
tissues. Thus, future needs of wet dressings include products that provide a moist
environment for cell repair and products that reduce pain during dressing changes.
There is a shift in preference for advanced wound care products from traditional
dressings in developed countries such as the U.S. Both antimicrobial dressings and
active therapies, such as fibrin sealants and bioactive dressings, are emerging segments,
especially in developing countries. Improved clinical results and faster healing rates are
driving the demand for these products. The expensive nature of these treatments makes
them feasible in only developed countries or in private hospitals in those developing
countries. The growth of minimally-invasive surgeries is also driving expansion towards
advanced wound care products that will allow for improved efficacy during these
technical surgeries. A model product for the minimally-invasive surgery sector would
allow for treatment in small, enclosed areas, and the product would be able to be applied
in all spatial directions.2,4
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Currently, there are approximately 50 million reported cases globally of patients
suffering from chronic and hard-to-close wounds, which have created a severe cost
burden to the world’s healthcare system.3,5 Additionally, the demand for portable and
easy-to-use devices is expected to grow over the coming years. Negative-pressure wound
therapy (NPWT) is the fastest growing product segment in developing countries. This
therapy is used to treat an array of wound situations, including traumatic, dehisced
wounds, partial-thickness burns, ulcers (e.g. diabetic, pressure or venous), flaps, and
grafts. The NPWT sector of the advanced wound care market is growing – the NPWT
segment generated revenue of $1.7 billion in 2013 and is expected to reach $2.1 billion
by 2018.2 This segment has several unmet needs as researchers are looking to improve
wound healing methods. These include the ability of new products to reduce the size of
the wound throughout treatment with the vacuum, and the need to minimize or remove
pain caused by debridement during dressing changes. An ideal product for the NPWT
sector would allow for cellular in-growth into a biocompatible and biodegradable
material while being able to withstand the subatmospheric pressure treatment.1
Taken together, there are several unmet needs in the wound therapy field. Both
acute and chronic wound care segments have untapped potential for where an optimal
wound therapy is needed. Traditional and modern wound therapies have been able to
satisfy wound healing situations for many years; however, there is the current trend to
tissue regeneration and healing through the use of tissue-engineered and bioactive
dressings.

CHAPTER THREE
METHODS
Preparation of Fibrin Foam.
ARTISS (4 IU thrombin, Baxter Healthcare Corporation) and TISSEEL (500 IU
thrombin, Baxter Healthcare Corporation) fibrin sealants were prepared as per
manufacturer’s instructions for use. Fibrin foam was generated by separating the
fibrinogen and thrombin components from the prefilled syringes of ARTISS into
individual syringes. As an example, 1 mL of fibrinogen was placed in one syringe and
1 mL of thrombin plus 2 mL air was taken up into another syringe. The Mix-F mixing
device (Baxter AG) was placed between the two syringes. The constituents were then
manually passed back and forth through the Mix-F device, with one pass equaling
moving through the Mix-F once. The number of passes through the Mix-F (ex. 2, 4, 6, 8,
etc.), concentration of thrombin (4 IU, 20 IU, 50 IU), and addition of supplemental
constituents, including human serum albumin (MP Biomedicals, LLC) and Tween 80
(Sigma Aldrich), were parameters varied during the analysis of fibrin foam preparations.
Preparation parameters and their results are listed in the subsequent Results section.
Fibrin Foam Kinetics Assay.
Fibrin foam was prepared as per above utilizing 1 mL of fibrinogen and 1 mL of
thrombin plus 2 mL of air in respective syringes. Six passes were used to generate fibrin
foam for the kinetics assessment. Once mixed, fibrin foam was applied to a vertical glass
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surface at 5 second intervals – starting at t = 0 seconds and finishing at t = 30 seconds.
Five hundred microliters (500 µL) of fibrin foam was dispensed from the syringe at each
time point. To evaluate the formation of fibrin foam at each time point, a visual yes-orno conclusion was given based on the following: yes: foam-like consistency and ability
to be applied to vertical/inverted surface without dripping/running; no: liquid
consistency and inability to be applied to vertical/inverted surface without
dripping/running. A yes-or-no designation was given at each time interval. The
experiment was repeated for a total of eight samples at each time interval.
Cell Culture.
Cell culture was performed on primary human umbilical vein endothelial cells
(HUVEC), primary normal human dermal fibroblasts (NHDF), and primary normal
human epidermal keratinocytes (NHEK) purchased from PromoCell. Cells were
maintained in respective growth media in a humidified atmosphere of 5% CO2 in air at
37°C. When subculturing, cells were washed with HEPES-HBSS (PromoCell),
suspended in trypsin/EDTA (0.025%/0.01%, PromoCell) for 5 minutes, and neutralized
with respective growth media. Cells were spun down at 130 x g for 4 minutes using a
swinging bucket centrifuge. Cells were counted using TC20 BioRad Cell Counter and
seeded in new tissue culture flasks containing fresh growth media. Cells were passaged
every three to four days during use.
Scanning Electron Microscopy and Pore Size Analysis.
ARTISS and fibrin foam clots were prepared and fixed with glutaraldehyde buffer
(Electron Microscopy Sciences), containing 0.2 M HEPES and MilliQ water, for SEM
preparation. For cell morphology analysis, 5 x 104 cells were seeded on ARTISS and
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fibrin foam clots for 24-48 hours prior to fixation in buffer. Subsequently, clots were
washed, serially dehydrated with ethanol, and dried with hexamethyldisilizane (Alfa
Aesar). Clots were allowed to air dry overnight thereafter. Clots were then mounted on
aluminum sample supports with carbon adhesive tape. Samples were sputter coated with
palladium gold in a Denton Desk IV Sputter/Etch Unit and analyzed in a FEI Quanta 650
FEG Scanning Electron Microscope.
Pore size analysis was performed on cross-sectional cuts of fibrin foam clots.
Briefly, SEM images were uploaded into FIJI ImageJ imaging software. Feret’s diameter
was measured for pores in each sample. Mean pore size was obtained for each fibrin
foam preparation. The numbers of pores measured to calculate mean values are shown in
the Results section. Percent porosity of ARTISS, fibrin foam, and polyurethane foam
samples was calculated using SEM images analyzed with FIJI ImageJ. Sample images
were assessed for mean gray scale values over a 300 x 300 pixel area. Two, independent
measurements were taken per image with at least three images per sample. Percent
porosity was calculated per equation 1. A total of 12 fibrin foam, 6 ARTISS, and 12
polyurethane foam (KCI) measurements were analyzed.
Porosity = mean gray scale / 255 x 100%

Eq (1)

Tensile and Wound Closure Strengths Testing.
For tensile strength testing, a specially designed dog-bone-shaped mold was used
to create ARTISS and fibrin foam clots of identical size and volume. The sample
thickness was 2 mm and had a width at the narrow middle part of 4 mm. The total
volume of the mold was 3.0 mL. Samples were allowed to cure in the mold for
15 minutes, and then placed in phosphate-buffered saline (PBS, HyClone) until use.
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Tensile testing was performed on MTS Criterion Model 42 (MTS Systems Co.). The
larger ends of each dog-bone-shape mold were placed into the pneumatic grips of the
MTS machine. Tensile loading was applied at a crosshead speed of 12.70 mm/min. The
maximum load at the sample failure and stress-strain curve was obtained; tensile strength
and elastic modulus were measured using the MTS Test Suite software version 3.0.1. Six
samples of each group were analyzed.
Wound closure strength was assessed using ASTM F2458 – 05 (Reapproved
2010), Standard Test Method for Wound Closure Strength of Tissue Adhesives and
Sealants.114 Briefly, porcine skin was cut into 10 cm long x 3 cm wide pieces. Pieces
were placed vis-à-vis along the 3 cm width margin. ARTISS and fibrin foam were
prepared and applied to a 0.5 cm region on each porcine skin piece along that same
margin. ARTISS and fibrin foam were measured at 3 mm thickness on the porcine skin
using a non-calibrated ruler. Samples were allowed to cure for 1 hour in PBS at 37°C.
Samples were loaded into the pneumatic grips of the MTS machine and tensile loading
was applied at a rate of 50 mm/min or until a full break occurred. Wound closure
strength and modulus measurements were obtained using the MTS software. The type of
break was recorded for each sample. Four samples from each group were measured.
Thromboelastography and Shear Strength.
Clot formation kinetics and strength were determined with thromboelastography
(TEG) using Thromboelastograph® Hemostasis Analyzer Model 5000 (Haemonetics
Co.) with the following deviations. Three-hundred sixty microliters (360 µL) of ARTISS
or fibrin foam were prepared per sample. For ARTISS, the samples were placed into the
assay cups and allowed to cure for 30 seconds before the analysis was started. For fibrin
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foam, the samples were mixed at t = 0 seconds, then allowed to sit in a syringe for
30 seconds prior to application into cups to normalize to ARTISS. The TEG analyses
were started at 30 seconds for both sets of samples and run at 37°C. The
thromboelastograph was calibrated with quality control samples before each use. TEG
Analytical Software version 4.2.3 was used to calculate the time to clot initiation (R,
minutes), time to clot firmness (K, minutes), alpha angle (α, degrees), maximal clot
strength (MA, maximum amplitude, mm), and shear elastic modulus strength (G,
dynes/cm2). Analyses were performed for at least 30 minutes or until the operating
software had calculated all mentioned parameters.
Shear modulus was further calculated from MA values in TEG to dynes/cm2 and
kilopascals (kPa) as per equation 2, where G has units of dynes/cm2 and 10,000
dynes/cm2 is equal to 1 kPa.115 Fourteen samples of ARTISS and sixteen samples of
fibrin foam were measured for TEG and shear strength.
G = 5000·MA / (100-MA)

Eq (2)

Permeability Analysis.
Sample fluid permeation was assessed using previously described techniques with
the following exceptions.116,117 The permeation coefficient (Ks) was calculated per
equation 3, where ƞ is the viscosity of the liquid (water, 0.001 Pascal seconds), L is the
length of the sample (mm), Q is the flow rate in time t, S is the surface area of the sample
(mm2), and P is the average pressure in the system (98 Pascals). To assess the fluid
permeability, ARTISS, fibrin foam, and polyurethane foam samples were fit to a
cylindrical apparatus and allowed to cure for 30 minutes. Two milliliters (2 mL) of water
stained with bromophenol blue (Sigma Aldrich) was applied to the top of each sample.
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Permeability was assessed after 1 hour when the sample radius, thickness of sample, and
height of permeabilized/dyed area were measured using a ruler. Lower values of Ks
indicated reduced permeability and smaller pore size in the matrixed network. Eight
samples were measured per group.
Ks = ƞ·L·Q / S·P

Eq (3)

Clot Compaction Assessment.
Compaction experiments were performed as previously described.116 Briefly,
1.5 mL microcentrifuge tubes were precoated with cooking oil spray (Conagra Brands)
and dried with a cotton swab. ARTISS and fibrin foam were prepared, and 1.0 mL was
dispensed into each tube. Clots were incubated at room temperature for 2 hours. After
2 hours, the clots were centrifuged at 4200 x g for 30 seconds. The supernatant volume
was removed and measured with a Hamilton syringe (Hamilton Co.). Percent
compaction was calculated as the ratio of the expelled supernatant volume to the original
clot volume (1.0 mL). Eight samples were measured per group.
Non-Invasive In Vivo Degradation Assay.
To measure the kinetics of in vivo degradation, fluorescently-conjugated fibrin in
either fibrin foam or ARTISS fibrin sealant was subcutaneously implanted in nude mice.
For this purpose, fibrin clots of defined volume (200 µL) were labeled by integration of
fluorescently-conjugated fibrinogen (125 µg/mL; Alexa Fluor 546 conjugate; Invitrogen).
The experiments were approved by the local animal research committee (Amt der Wiener
Landesregierung, Vienna, Austria) and animals were treated according to the National
Institute of Health guidelines. A total of 6 nude mice (BALB/C nu/nu; female; 20-30 g;
Institut für Labortiertechnik und Gentechnik, Austria) were implanted with fibrin clots
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under the skin over each shoulder and proximal to each hock. Animals were treated
preoperatively and on the following 3 days with carprofen (2.5 mg/kg Rimadyl, Pfizer,
Austria). The fluorescence of the fibrin matrix was non-invasively followed and
quantified over 14 days using a multispectral imaging system (Maestro Imaging System,
CRI Inc.). The images were acquired using the CCD frame at 2 x 2 binning and resulting
spectral data series unmixed using the identical spectral library for every cube. This in
vivo degradation analysis was performed by the Ludwig Boltzmann Institute on behalf of
Baxter Healthcare Corporation.
Lactate Dehydrogenase Cell Viability Assay.
ARTISS fibrin sealant, fibrin foam, and polyurethane foam samples were
prepared and placed in 24-well plates and set in a 37°C/5% CO2 incubator for
30 minutes. A specific number of cells from each cell line (HUVEC, NHDF, and NHEK)
were isolated to give a final concentration of 2 x 104 cells per well. Cells were cultured
on the samples, allowed to attach for 1 hour, and then additional media was placed into
the wells. At 2, 24, and 48 hours after cell seeding, lactate dehydrogenase (a marker of
cellular death) was analyzed using a colorimetric assay and per manufacturer’s
instructions (Promega). Briefly, 50 µL of supernatant was removed from each well,
placed into a 96-well plate, mixed with 50 µL of substrate solution, and allowed to
incubate for 30 minutes at room temperature. Fifty microliters (50 µL) of STOP solution
(solution within LDH cell viability kit) was added to all wells after the 30 minute
incubation. Wells were then analyzed for absorbance at 490 nm on a SpectraMax M5e
microplate reader. Cell viability was quantified by the average absorbance at each time
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point for the various cell conditions. Eight samples were measured for each cellular
condition.
AlamarBlue Metabolic Assay.
HUVEC, NHDF, and NHEK cells were cultured and isolated to a final
concentration of 5 x 104 cells per well. Cells were cultured on ARTISS fibrin sealant,
fibrin foam, and polyurethane foam for 1 hour in a 24-well plate before an additional 900
µL of media was added to each well. After 4 hours of incubation at 37°C/5% CO2, 100
µL of AlamarBlue reagent (Invitrogen, Thermo Fisher Scientific) were added to each
well. At 2, 24, 48, and 72 hours after the addition of AlamarBlue, 50 µL of supernatant
was removed, placed into a 96-well plate, and read in fluorescence mode with an
excitation wavelength of 570 nm and emission wavelength of 585 nm. Readings were
performed on a SpectraMax M5e microplate reader. Cellular metabolism and viability
was assessed using average fluorescence units at each time interval. Four samples were
measured per cell condition.
Confocal Microscopy for Cell Viability.
One milliliter of ARTISS fibrin sealant or fibrin foam was placed into a 24-well
plate. Primary HUVEC, NHDF, and NHEK cells at a final concentration of 1 x 105 cells
per well were seeded on the clots for 48 hours in a 37°C/5% CO2 incubator. After
48 hours, clots containing cells were transferred and inverted onto MatTek dishes. Two
milliliters of HBSS (PromoCell) were added to each sample. ReadyProbes® Cell
Viability live/dead and wheat germ agglutinin stains (Thermo Fisher Scientific) were
added to the HBSS solution. Samples were covered from light and incubated at room
temperature for 15 minutes. Images of the samples were taken using a Nikon A1R
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Confocal Microscope at magnifications noted in the images. Image manipulation and
compilation was performed using Nikon NIS-Elements Software Version 3.10.
Cytotoxicity Assay.
NCTC clone 929 cells (ATCC #CCL1) were cultured at a concentration of 1.3 x
105 cells per well. Cells were incubated for 24 hours in a humidified atmosphere of 5%
CO2 in air at 37°C. After 24 hours and according for ISO 10993-5 – Biological
Evaluation of Medical Products – fibrin foam samples were placed on top of the cells.118
Positive control (powder free latex gloves, Rubbercare) and negative control (Baxter
polyolefin material) were also tested and placed on cells. Cells and test samples were
incubated for an additional 24 hours. After this elapsed time, test samples were removed
from each well and 2% Crystal Violet solution (Sigma Aldrich) was added to each well to
stain the cells. The cells were examined microscopically based on the ISO guidelines of
toxicity ratings (below). Six fibrin foam samples were tested, and three positive and
three negative controls were also analyzed.
Rating

Pass/Fail

0

Pass

Description

No detectable zone around
or under the specimen
1
Pass
Some degenerated cells
under the specimen
2
Pass
Zone of degenerated cells
limited to the area under the
specimen
3
Fail
Zone of degenerated cells
extends specimen size up to
1.0 cm
4
Fail
Zone of degenerated cells
extends farther than 1.0 cm
beyond specimen
Table 7. Toxicity Ratings for ISO 10993-5. Adapted from ISO 10993-5.118
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Three-Dimensional In Vitro Wound Assay.
Six hundred microliters (600 µL) of 5 mg/mL PureCol EZ Gel (Advanced
BioMatrix, Inc., Sigma Aldrich) collagen gels were formed in a 24-well plate. Gels were
incubated at 37°C/5% CO2 for 90 minutes to allow for full polymerization of the
collagen. Primary HUVEC, NHDF, and NHEK cells were trypsinized. A specific
number of cells from each line were isolated to give a final concentration of 3 x 104 cells
per gel and stained with Vybrant DiO (Life Technologies of Thermo Fischer Scientific).
After staining, the cells were washed three times with media, and then seeded onto the
collagen gels. After 4 hours, a 2 mm biopsy punch (V. Mueller) was used to punch
regions out of the collagen gel. Careful pipetting was used to remove remainder of the
collagen debris from the punch region. The regions were then filled with PureCol EZ
Gel, ARTISS fibrin sealant, fibrin foam, or polyurethane foam and supplemental media
was placed on gels. Gross migration of cells was assessed at 24 and 48 hours using a
Nikon Eclipse LV100 Upright Microscope with Nikon Camera. Images were taken at 4x
magnification at each time point to analyze the migrated cells and wound margins.
Murine Wound Model.
A dermal skin excision wounding model was performed as follows with the
assistance of the W. Keith Jones Laboratory from Loyola University Chicago in
collaboration with Baxter Healthcare Corporation. BKS.Cg-Dock7m +/+ Leprdb/J (db/-)
mice (Jackson Laboratories, male, 8-12 weeks of age) were anesthetized using isoflurane
(1.5 L/min) and buprenorphine (0.5 mg/kg i.p.) to effect. The dorsal aspect of the thorax
was shaved, draped, and three butadiene scrubs were performed. A 6 mm biopsy punch
was used to make four excision wounds (1 cm apart) in the sterile field. Each of the four
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wounds was treated separately and covered using experimental materials and dressings
(Fig. 11). Briefly, ARTISS fibrin sealant and fibrin foam were two treatments, compared
to control (no dressing) and polyurethane foam dressing (KCI). Tegaderm (3M Medical,
USA) and/or cohesive tape were put on the mice to prevent access to the wounds, and the
mice were individually caged to prevent damage by other animals to the wound site.
Dressings were changed and wounds measured and photographed at days 3, 7, 10, and 14
and depilatories used to remove growing hair as needed. At day 3, day 7, and day 10,
mice were anesthetized and dressings changed. While uncovered, photographs with ruler
were taken to document wound size. The wounds were re-dressed and the animals
recovered and housed as above. At day 7 or day 14, mice were anesthetized using
isoflurane and ketamine/xylazine (10 mg/mL and 0.2 mg/mL i.p.). When non-responsive
to toe pinch, the dorsal aspect of the thorax, including the wounds, was excised, then
prepared and fixed for histological analysis. The hearts were also harvested resulting in
death of the mice.
Animal procedures were approved by Loyola University Chicago Institutional
Animal Care and Use Committee (IACUC) and conducted in accordance with the Guide
for the Care and Use of Laboratory Animals and applicable United States animal welfare
regulations in an AAALAC-accredited facility. The animals utilized in this experiment
all received humane care.
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Figure 11. Overview of Murine Model Surgical Procedure. Photographical
representation of surgical procedure and treatment of mice during murine model. Mice
were subjected to 2 mm punch biopsies on their dorsum. Each would was treated
separately with one of four treatment options. The dorsal surface of the mice was them
covered to prevent any disruption to wound and treatment sites.
Wound Closure Measurement.
Using a digital camera, images of the wounds were obtained after wounding, after
treatments, and at each scheduled dressing change (days 0, 3, 7, 10, and 14). Images
were uploaded to a computer, and using imaging software (FIJI ImageJ), the wound area
was measured. FIJI ImageJ imaging software was used to blindly measure the wound
area by tracing the wound margin with a fine-resolution computer mouse and calculating
the pixel area.119 Wound size area (cm²) from each day was measured as compared to
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day 0. A wound was considered completely closed when the wound area was equal to
zero (grossly). All area measurements are in cm².
Histological and Pathological Analyses.
The wounds and surrounding tissue were collected and placed in formalin for
histopathologic evaluation on days 7 and 14. Polyurethane foam dressings were collected
for histopathologic evaluation on dressing changing days (days 3, 7, and 10) and
submitted to Loyola University Medical Center’s Histology and Pathology departments.
Histopathologic evaluation was performed on the collected tissue and samples. Analysis,
including hematoxylin & eosin (H&E) and Masson’s Trichrome staining, was read by an
independent and blinded pathologist at Loyola University Medical Center.
The main histological parameters analyzed for wound healing were:
reepithelialization, neovascular proliferation, acute and chronic inflammation, and
collagen deposition. These parameters were scored on a 0-3 scale (below).120 A total of
12 samples were analyzed per treatment per time point for all parameters except collagen
deposition (n = 4 per treatment per time point). Each histological slide contained 4-6
slices of wound sample with scores being representative for the sample overall.
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Parameter
Reepithelialization

0
None

1
Partial

Neovascular
Proliferation

None

Up to 5
vessels per
field
Scant

2
Complete, but
immature/thin
Up to 6-10
vessels per field

3
Complete;
mature
More than 10
vessels per
field
Abundant

Acute
None
Moderate
Inflammation
Chronic
None
Scant
Moderate
Abundant
Inflammation
Collagen
None
Scant
Moderate
Abundant
Deposition
Table 8. Histological Parameter Scoring for In Vivo Wound Model. Scoring scale
adapted from reference Abramov et al.120

Additionally, epithelial maturation, granular tissue formation, and granular tissue
maturation were assessed on a yes-or-no basis. The degree of granular tissue
formation/maturation was determined by the structure and alignment of fibroblasts in the
wound area.
Negative-Pressure Wound Therapy Feasibility.
Porcine skin samples (obtained from Baxter R&D) were thawed and cleaned, and
hair was removed. A 12-mm full-thickness biopsy punch was created in the porcine skin.
ARTISS or fibrin foam was prepared and placed into the wound punches. Samples were
allowed to cure for 5 minutes, 30 minutes, 1 hour, and 2 hours in the wounds. At each
time point, V.A.C. Freedom NPWT System (KCI) was placed over the treated wounds
and vacuum pressure (-200 mmHg) was applied for 2-5 minutes. Images of the system
apparatus, wounds, and treatment were taken using Nikkor 42x Wide Optical Zoom ED
VR Cool Pix P510. At least three samples were performed for each treatment group at
each time point.
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Statistical Analysis.
All data collected in this body of work was expressed as mean ± SD. Sample
sizes are stated within each experimental results section. Pairwise differences between
products were evaluated using the Wilcoxon Mann Whitney test. For the murine model,
the means and standard deviations of wound size were calculated initially and at followup time points for each treatment for 12 or 24 mice. A linear mixed effects model was
specified to predict wound size as a function of treatment, time, and the treatment by time
interaction, and included a random intercept for mice to account for possible correlation
due to repeated measures. The effect of treatment at each time point was tested. Least
squares mean differences in wound size by treatment were presented at day seven to
assess differences due to treatment. P-values < 0.05 indicate samples are significantly
different. Statistical analyses were performed with the support of Baxter Healthcare
Corporation Biostatistics and Loyola University Chicago Biostatistics Core.

CHAPTER FOUR
RESULTS
Aim 1: To determine the impact of aeration on the physical, biomechanical, and
biocompatibility properties of fibrin foam.
Optimal preparation of fibrin foam. The preparation of fibrin foam has several
variables which could be changed to generate a variety of fibrin foam entities. Fibrin
foam is created using a dual-syringe apparatus (Fig. 9A), where the fibrin sealant
constituents are passed through the mixing device (Fig. 9B). This aeration process yields
a foam-like, porous fibrin network compared to the dense fibrin matrix of commerciallyavailable sealants (Fig. 10). To optimize the preparation of fibrin foam, I varied three,
key factors. These included the number of passes through the Mix-F mixing device,
thrombin concentration for speed of clot formation, and additional foaming agents (i.e.
HSA and Polysorbate 80). With each preparation variant, the acceptance criteria were
the following: 1) manual ease of mixing 2) foam-like, porous consistency 3) mean pore
size < 200 µm. The pore size criterion was chosen based on several critical cellular
processes that have been noted in the literature that require a mean pore size distribution
less than 200 µm, including angiogenesis, skin regeneration, and fibroblast cell
migration/proliferation, which have optimal pore size ranges from 160-270 µm, 20-125
µm, and 100-250 µm, respectively.15
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Previous Baxter research dealing with the mixing of fibrin foam indicated either
syringe could contain the air and an even number of passes was to be used to have equal
mixing between the syringes.24-27 This research had shown six or eight passes to be ideal
for fibrin foam generation, which was solely based on the void volume remaining in the
syringes during mixing and included no other acceptance criteria. At six or eight passes,
the void volume was zero, meaning all constituents were incorporated into the foam.
However, and to assess all possible parameters, the experimental variants used in the
preparation, mixing, and pore size analyses are shown in Tables 9 and 10.
Fibrin Foam
Preparation

4 passes

6 passes

8 passes

Failure Point

4 IU

Y

Y

Y

14

20 IU

Y

Y

Y

9

50 IU

Y

Y

N

6

4 IU +
10% HSA

Y

Y

Y

14

Table 9. Gross Mixing Assessment of Fibrin Foam Preparations. Y = total number of
passes were achieved; N = total number of passes not achieved (i.e. clogging of device or
failure to mix). Failure point was the maximum passes reached during mixing over the
samples tested. Six total samples were measured for each preparation.
First, to assess ease of mixing with the various preparations, fibrin foam was
prepared and subjected to differing number of passes through the Mix-F mixing device
and the maximum number of passes before mixing failure (i.e. clotting/clogging). For all
mixing experiments, the setup in Figure 9 was used with the following ratio of
constituents – 1 mL thrombin + 2 mL air in one syringe; 1 mL fibrinogen in the second
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syringe. From a gross and human factors perspective, the number of passes and added
constituents to create fibrin foam was tested. The number of passes was varied from 2, 4,
6, 8, and maximum passes achievable. An even number of passes was chosen for all
experiments as to have the thrombin and fibrinogen constituents equally mixed in the two
syringes.
Higher concentrations of thrombin and human serum albumin (HSA) were also
tested in this portion of the study. Thrombin concentration, which dictates the speed at
which the fibrin clot forms, was varied from 4IU (current ARTISS formulation) up to
50 IU. HSA was adjusted to a final concentration of 10% or 50% HSA greater than that
of the current formulation. HSA was a chosen constituent to adjust because of the ability
of albumin to stabilize the fibrin clot and increase foaming abilities. Polysorbate (Tween)
80, a known surfactant, was also tested but failed mixing feasibility assessment as this
preparation clogged the Mix-F device and did not allow for proper mixing through the
device. Therefore, Tween preparations were not included in further analyses.
As shown in Table 9 (and A1), the 4 IU thrombin preparation of fibrin foam was
able to be passed through the mixing device up to 14 times before failure of the device
occurred. Failure was constituted as clogging of the Mix-F device. The 20 IU and 50 IU
thrombin samples, however, clotted too rapidly and only were able to achieve a
maximum of 9 and 6 passes through the device, respectively.
The microscopic matrix of fibrin foam was assessed next via scanning electron
microscopy. SEM was used to measure the pore sizes of the various fibrin foam
preparations (Fig. 12). Pore size is a crucial determinant in the overall structure and
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function of matrices and scaffolds, as mentioned previously. Too small and the cell
migration is limited; while too large of pores can reduce ligand density.

Figure 12. SEM Micrographs of Fibrin Foam Preparations. SEM micrograph images
of several fibrin foam preparations. Preparations were varied by either the number of
passes through mixing device or by additive constituents (i.e. increase in thrombin
concentration). A) 4 Passes + 4 IU fibrin foam B) 6 Passes + 4 IU fibrin foam C) 8
Passes + 4 IU fibrin foam D) 6 Passes + 4 IU fibrin foam E) 6 Passes + 20 IU thrombin
fibrin foam and F) 6 Passes + 50 IU thrombin fibrin foam. Scale bars: 1 mm (A-C), 100
µm (D-F).
The measured pore size distributions for all fibrin foam preparations are shown
below in Figures 13 and 14. Table 10 displays the quantified means for all preparations
(in microns) and the number of pores analyzed, which is visually shown in Figure 14.
While the distributions vary from large distributions of pores in the lower number of
passes to more tightknit pore sizes as the passes increase, it was noted that all
preparations have mean pore sizes that fall below the accepted range of 200 µm (Table
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10). Due to the large standard deviations for each distribution, there was no statistical
difference among the groups.

Figure 13. Pore Size Measurements of Fibrin Foam Preparations (Passes Varied).
Histogram representations of pore size distributions for A) Minimum (2) Passes + 4 IU
fibrin foam B) 4 passes + 4 IU fibrin foam C) 6 Passes + 4 IU fibrin foam D) 8 Passes + 4
IU fibrin foam and E) Maximum passes (14) + 4 IU fibrin foam. Quantified data for
Figure 13 is found in Table 10.
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Figure 14. Pore Size Measurements of Fibrin Foam Preparations (Additives
Varied). Histogram representations of pore size distributions for A) 6 passes + 4 IU +
10% HSA fibrin foam B) 6 Passes + 4 IU + 50% HSA fibrin foam C) 6 Passes + 20 IU
thrombin fibrin foam and D) 6 Passes + 50 IU thrombin fibrin foam. Quantified data for
Figure 14 is found in Table 10.
As the previous Baxter studies detailed, the number of passes to incorporate all
constituents into the foam was 6 or 8 passes. The 20 IU preparation reached 9 passes and
the 50 IU only reached 6 passes, respectively. These failure points were too close to the
optimal range of passes (e.g. 6 to 8), which would not allow for a margin of error in a
surgical use and preparation of the foam. Clogging and other mixing failures would
likely occur at a higher frequency with these preparations. Thus, to ensure no future
human factor issues with mixing and preparation of fibrin foam, the higher concentration
thrombin preparations were eliminated from consideration. Next, I took into
consideration the pore mean distribution of all foam preparations. As shown in Figure
15, there was no discernable difference in pore size distributions among the fibrin foam
preparations.
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All preparations met the mean pore size parameter; however, and after factoring
in the mixing analyses and acceptance criteria, the 6 passes + 4 IU preparation was the
optimal choice for fibrin foam. This preparation would allow for ease in generating the
foam in a surgical situation and is well within the acceptable range for mean pore size
(155 µm) for use in wound healing applications. There was no added effect(s) from HSA
throughout this initial characterization, thus it was excluded from any major analyses
moving forward.

Min (2
Passes)
+ 4 IU

4 Passes
+ 4 IU

6 Passes
+ 4 IU

8 Passes
+ 4 IU

Max (14
Passes)
+ 4 IU

6 Passes
+ 20 IU

6 Passes
+ 50 IU

6 Passes
+ 4 IU +
10% HSA

6 Passes
+ 4 IU +
50% HSA

Mean
Pore
Size
(µm)

199.3 ±
93.8

152.2 ±
66.8

155.5 ±
58.9

151.8 ±
46.0

117.2 ±
49.7

152.6 ±
54.8

134.5 ±
46.7

156.7 ±
55.3

113.21 ±
35.2

Pores
Counted

70

177

277

193

166

118

158

136

180

Table 10. Mean Pore Sizes of all Fibrin Foam Preparations. The quantified mean
pore size distributions (± SD) for all fibrin foam preparations are shown. The numbers of
pores counted for each preparation are detailed as well. No significant differences were
found among preparations. IU: international units of thrombin; HSA: human serum
albumin.
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Figure 15. Mean Pore Sizes of Fibrin Foam Preparations. Mean pore size
distributions (± SD) for all fibrin foam preparations (Table 10) are shown. No significant
differences were found among groups.
Once chosen as the optimal preparation, further analyses in this study were
performed on the 6 passes + 4IU fibrin foam. First, as seen in Figure 16, the rate of
formation of fibrin foam was assessed in order to confirm that exact preparation
procedure for the generation and application of fibrin foam. This test was performed by
preparing fibrin foam, then waiting 0-30 seconds at 5 second intervals before applying
the foam to a vertical surface. Per this experiment, an acceptable outcome was a foam
having the viscosity to remain on a vertical surface without dripping or running, as this is
one of the differentiating characterisitcs of fibrin foam compared to ARTISS and other
fibrin sealants. Figure 15 details the number of positive outcomes at each time point (n =
8 per time point). After 20 seconds post-mixing, fibrin foam is able to be applied with
100% positive outcomes from a consistency standpoint. Thus, this 20-second set time
prior to application was another step in the preparation of the 6 passes + 4 IU optimal
fibrin foam.
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Figure 16. Kinetic Assessment of Fibrin Foam Formation. Fibrin foam (6 passes + 4
IU) was prepared and allowed to set in syringe for multiple time intervals. Fibrin foam
was applied to a vertical surface and each sample’s consistency was noted. An outcome
was deemed positive based on formation of foam-like consistency and ability to hold on
vertical surface without running. Percent of total positive outcomes is shown at each
time point. A total of eight samples were analyzed at each time interval.
Taken together, the optimized fibrin foam preparation is generated from the
components of the commercially-available fibrin sealant, ARTISS. The constituents of
ARTISS are used at a ratio of 1 mL fibrinogen to 1 mL of 4IU thrombin + 2 mL of air to
create fibrin foam as it is passed six times through the Mix-F mixing device. This
preparation has a mean pore size of 155 µm and is allowed to set in the syringe for 20
seconds prior to application. Hereafter, this specific preparation of fibrin foam was used
for all subsequent experiments and testing, and it will be referred to as solely as “fibrin
foam”.
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Biomechanical and structural characterization of fibrin foam. With the fibrin
foam preparation optimized to 6 passes + 4IU thrombin, biomechanical testing was
performed to study the impact of aeration on fibrin foam as compared to that of ARTISS
fibrin sealant. The following portion of the study details both biomechanical and
structural analyses of fibrin foam.
Thromboelastography (TEG) is a coagulation assay used to evaluate the
efficiency of clot formation and clot viscoelastic properties. TEG analyzes a set of
specific parameters associated with clot kinetics and formation. These include: reaction
time (R), or time until initial fibrin formation; clot formation time (K), or the measure of
rapidity to reach clot strength; α angle, or the speed of clot strengthening; maximum
amplitude (MA), or ultimate clot strength; and shear elastic modulus strength (G), or the
clot firmness.121 TEG was employed to understand any perturbations in clot formation
and kinetics through the aeration process of ARTISS into fibrin foam and the impact of
these changes.
Figure 17 depicts a thromboelastograph readout of fibrin foam versus ARTISS.
The TEG analyses were normalized to time of preparation as described in the Methods
section. This figure shows fibrin foam (green) with a much steeper angle to clot
formation than ARTISS, as reflected in the significantly higher alpha angle (Table 11,
p<0.001). Table 11 (and Table A1) shows the remaining TEG parameters as compared
between ARTISS and fibrin foam preparations with significant differences (p<0.001) in
the R and K values as well leading to the conclusion of faster clot kinetics for fibrin foam
compared to ARTISS. There were similar measured values for maximum clot strength
(MA) and shear elastic modulus strength (G), which shows fibrin foam and ARTISS,
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have comparable clot strengths even after aeration. Expanding from the TEG analysis, a
shear strength computation was performed to extrapolate additional data on the
biomechanical attributes of fibrin foam. As referenced in the literature, shear strength, G,
is often measured in a magnitude of Pascals.115 Table 12 (shear strength) details similar
values for G of both fibrin foam and ARTISS as would be expected from the values in
the TEG analysis. These values, however, are used to correlate between this study and
published literature for which the values of ARTISS and fibrin foam are consistent.
Through literature searches and previous research, the shear strengths for fibrin sealants
are on average 1-2 kPa.115,121

Figure 17. Thromboelastography Assessment of Fibrin Foam. Thromboelastography
comparison of fibrin foam versus fibrin sealant. Fibrin foam (green) and ARTISS fibrin
sealant (black) were analyzed on a thromboelastograph for 30 minutes. Associated
parameter data from the plot found in Table 11.
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Parameter
R (clot formation, min)
K (degree of elasticity,
min)
Maximum amplitude
(MA; clot strength, mm)
G (shear modulus,
dynes/cm2)
α-angle (clot kinetics,
degrees)

Fibrin Foam
0.2 ± 0.0*
0.8 ± 0.0*

ARTISS Fibrin Sealant
0.6 ± 0.4
4.5 ± 1.8

88.1 ± 1.8

85.0 ± 6.6

38.0 ± 6.5

35.5 ± 18.9

86.0 ± 0.7*

49.8 ± 11.4

Table 11. Thromboelastography Parameter Measurements of Fibrin Foam.
Thromboelastography results obtained for fibrin foam and commercially-available fibrin
sealant. Fibrin foam showed decreased time to initial fibrin clot formation (R) and a
lower degree of elasticity (K), which indicates faster clotting. Additionally, fibrin foam
had larger α-angles correlating faster clot-forming kinetics. The fibrin sealant, however,
had slightly greater clot (MA) and shear strengths (G) comparatively. Sample size: n =
16 for fibrin foam, n = 14 for ARTISS. *Significant difference (p < 0.001).
The mechanical properties of fibrin foam were also examined to show its ability
to function as a proper wound therapy, including having elasticity to permit motion
within tissue, ability to resist linear and shear stresses, and tensile strength to resist
fragmentation.14 Tensile strength and elastic modulus were examined using two, similar
methods. First, a dog-bone-shaped mold apparatus was used to measure tensile strength
and modulus. The tensile strength of fibrin foam (0.40 ± 0.07 MPa) was significantly
lower than ARTISS (0.87 ± 0.27 MPa) (Fig. 18A); however, ARTISS (0.076 ± 0.01 MPa
compared to fibrin foam 0.047 ± 0.01 MPa) was shown to be significantly stiffer with its
higher elastic modulus (p < 0.05) (Fig. 18C). Similar results were noted in an ASTM
wound closure experiment that utilized vis-à-vis porcine skin samples with either sealant
preparation serving as a wound treatment holding the porcine skin pieces together.
ARTISS, again, had a significantly greater wound closure strength (p < 0.05), but no
observable difference was noted in wound closure elastic moduli (Fig. 18B, 18D). The
tensile and wound closure strengths as well as associated moduli values are comparable
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with previous research performed on fibrin sealants. The range for tensile and wound
strengths is 3 kPa to 0.2 MPa and 1 kPa to 0.13 MPa for elastic moduli.122,123 Thus, fibrin
foam – even with decreased biomechanical strengths relative to ARTISS – should be
considered a viable and mechanically-sound wound therapy candidate based on data from
previous data on fibrin sealants.122,123

Figure 18. Biomechanical Comparison of Fibrin Foam and ARTISS Fibrin Sealant.
Tensile strength and elastic modulus were obtained using a Materials Testing System for
the tensile strength test. Wound closure strength and modulus were analyzed through use
of ASTM F2458-05, which used porcine skin segments as scaffold to recreate a wound
environment. A) Significant differences between ARTISS and fibrin foam for tensile
strength (*p < 0.05) B) and wound closure strength (*p < 0.05). C) Significant increase
in elasticity of fibrin foam compared to ARTISS observed for elastic modulus (*p <
0.05). D) No significant differences were shown for wound strength modulus. Sample
sizes: tensile strength and modulus (n = 6 per group); wound closure strength and
modulus (n = 4 per group).
While the biomechanical properties are important for wound therapy, I also
assessed the effects of the aeration process on the structural characteristics of ARTISS
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used to generate fibrin foam. In the following assessments, ARTISS (non-aerated fibrin
sealant) and polyurethane foam dressing (a current wound therapy) were examined for
comparison purposes. Polyurethane foam dressings (KCI, Inc.) are often used in
negative-pressure wound therapy applications because of their highly porous scaffold
structure (pore sizes: 400-600 µm). SEM images of each of the three test samples are
displayed in Figure 19. As seen in these micrograph images, the polyurethane foam
dressing sample has vastly larger pore sizes compared to that of fibrin foam and ARTISS.
Fibrin foam does display its evenly dispersed range of pores in this cross-sectional
sample, while ARTISS shows its tightly-bound fibrin network.

Figure 19. SEM Analysis of Wound Treatments. SEM images of each wound
treatment. A) Fibrin foam. B) Polyurethane foam dressing. C) ARTISS fibrin sealant.
Each treatment image is labeled with respective pore size (via SEM/FIJI ImageJ analysis)
and porosity percentage. Scale bars: 1 mm (panels A, B), 30 µm (panel C).
The focus then shifted to studying the three-dimensional structure of fibrin foam.
This entailed analysis of permeability, which is a crucial attribute for wound healing
biomaterials. Permeability, in the instance of fibrin foam/sealant, is dependent on fibrin
density and porosity. These properties were additionally studied through compaction and
porosity experiments. As shown in Table 12 below, fibrin foam had a significant
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increase in compaction percentage (24.7 ± 1.6% compared to 7.4 ± 1.4% of ARTISS)
indicating a more porous fibrin matrix within the foam, as would be expected through the
aeration process. Porosity (72.5 ± 8.3% compared to 47.7 ± 6.8%) and fluid permeability
(8.3 x 10-8 ± 2.3 x 10-9 mm2 compared to 6.1 x 10-8 ± 1.2 x 10-8 mm2) were also
significantly higher (p < 0.05) in fibrin foam compared to the fibrin sealant. While
polyurethane had significantly better fluid permeability (Ks = 1.3 x 10-7 ± 1.0 x 10-8 mm2
of polyurethane compared to 8.3 x 10-8 ± 2.3 x 10-9 mm2 of fibrin foam, p < 0.05), fibrin
foam was significantly more porous (72.5 ± 8.3% to 42.8 ± 5.4%, p < 0.05) due to the
thicker fibers in the polyurethane matrix.
The results of the fluid permeation experiments displayed significant differences
between ARTISS and fibrin foam, and polyurethane foam compared to both fibrin foam
and ARTISS. This permeability trend among the three test samples is directly related to
the increases in pore size from ARTISS (0-50 µm) to fibrin foam (100-250 µm) to
polyurethane foam (400-600 µm) (Figure 19). All measured permeability constants fall
within range of other tissue engineering and wound healing scaffolds (ex. range: 1 x 10-7
to 1 x 10-10 mm2).116,117 These combined results show fibrin foam is able to withstand the
stresses and forces within a wound cavity, and fibrin foam also obtains advantageous
attributes after aeration, such as increased fluid permeability and porosity, from that of
commercially-available fibrin sealants and current wound therapies.
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Shear Strength (kPa)

Compaction (%)

Permeability (K, mm²)

Porosity (%)

ARTISS Fibrin
Sealant

3.6 ± 1.9

7.4 ± 1.4

6.1 x 10-8 ± 1.2 x 10-8

47.7 ± 6.8

Fibrin Foam

3.8 ± 0.65

24.7 ± 1.6*

8.3 x 10-8 ± 2.3 x 10-9**

72.5 ± 8.3***

Polyurethane
Foam

ND

ND

1.28 x 10-7 ± 1.0 x 10-8@

42.8 ± 5.4

Table 12. Structural Assessment of Fibrin Foam. Shear strength, fibrin compaction
percentage, fluid permeability, and percent porosity of ARTISS fibrin sealant and fibrin
foam. Shear strength indicates no significant difference between the two conditions.
However, significant increases in compaction percentage (*p = 0.0009), fluid
permeability (**p = 0.0034) and percent porosity (***p = 0.0012 FF vs ARTISS and
polyurethane foam) were determined for fibrin foam as compared to the fibrin sealant.
Additionally, polyurethane foam was demonstrated significantly higher permeability
compared to both fibrin foam and ARTISS (@ p < 0.05). Sample sizes: n = 14-16 (shear
strength), n = 8 (compactibility and permeability), and n = 6-12 (porosity). ND: not
determined.
Lastly, and to determine the kinetics of in vivo degradation, fluorescently
conjugated fibrinogen was used to label both ARTISS fibrin sealant and fibrin foam as
performed by Ludwig Boltzmann Institute in collaboration with Baxter. Each preparation
was subcutaneously implanted in nude mice. As seen in Figure A1, there was no
difference in the overall degradation rate of fibrin foam from that of ARTISS over the
fourteen-day period. However, it was positive to see the biodegradability of fibrin foam
in vivo of up to two weeks’ time, which overlaps greatly with the wound healing process.
These results coincide with previously performed in vitro degradation studies performed
on fibrin sealants (internal Baxter research), which found their fibrin sealants remain
within a degradative environment for approximately 14 days.
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Cellular biocompatibility analyses of fibrin foam. An important consideration
with the characterization of this novel biopolymer was ensuring the preservation of
cellular biocompatibility. While ARTISS fibrin sealant is a commercially-available
fibrin sealant and has been marketed for years, the permutations in matrix structure
within fibrin foam could cause cellular distress. As seen in the literature, pore size
environment is a determining factor in cell migration and proliferation.15 Here, to assess
cellular viability, a lactate dehydrogenase (LDH) assay was used. Primary human
umbilical vein endothelial cells (HUVEC), primary normal human dermal fibroblasts
(NHDF), and primary normal human epidermal keratinocytes (NHEK) were cultured on
ARTISS and fibrin foam clots as well as polyurethane foam dressings. Polyurethane
(PU) foam, a current therapy in acute and chronic wounds, was also analyzed in these
experiments as its porous matrix is attributed to its resilience in wound healing
applications, such as negative-pressure wound therapy. This colorimetric assay
quantitatively measures LDH released into the media from damaged cells as a biomarker
for cellular viability. The extracellular LDH in culture media, in combination with
diaphorase, enzymatically converts tetrazolium into a red formazan product, which was
measured spectrophotometrically.
As Figure 20 illustrates, several cellular conditions were analyzed at each time
point. As expected, Media Alone, Cells + Media, ARTISS + Cells, Fibrin Foam + Cells,
and Polyurethane Foam Alone conditions all resulted in low average absorbance levels at
2, 24, and 48 hour time points. This correlates to minimal cell death and high level of
cell viability in each condition, including fibrin foam. Conversely, the LDH positive and
Cell Lysis conditions resulted in increased levels of average absorbance, as these wells
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contained high concentrations of LDH in the cell media (i.e. non-viable or dead cells).
ARTISS and fibrin foam were both significantly different (p < 0.05) from the LDH
positive condition, confirming cellular viability in each condition. PU + Cells begin to
show increasing levels of absorbance (i.e. increased levels of LDH in supernatant) at 24
and 48 hours (Fig. 20 middle and lower panels). Compared to Media Alone, PU + Cells
(NHDF, NHEK) show significant differences (p < 0.05) at 24 and 48 hour time points,
which may denote increases in cell death when cells are seeded on PU foam dressings.
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Figure 20. Lactate Dehydrogenase (LDH) Assay for Cellular Biocompatibility.
HUVEC, NHDF, and NHEK cells were cultured on fibrin sealant and fibrin foam clots as
well as polyurethane (PU) foam dressings for 2, 24, and 48 hour time points. ARTISS
and fibrin foam (FF) were both significantly (*p < 0.05) different from the LDH positive
condition, showing cell viability in each case. Compared to Media Alone, PU + NHEK
and PU + NHDF show significant differences (#p < 0.05) at both 24 and 48 hour time
points; this may denote cell death. Eight samples were performed for each group.
Additionally, cellular biocompatibility was determined on the basis of the
metabolic state of the cells (Fig. 21). When cells are viable, they maintain a reducing
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environment within the cytosol of the cell. Resazurin, the active ingredient of
AlamarBlue (AB) reagent, is a non-toxic, cell permeable compound that is blue in color
and non-fluorescent. Upon entering cells, resazurin is reduced to resorufin, a red-colored
compound and highly fluorescent. Viable cells continuously convert resazurin to
resorufin, increasing the overall fluorescence and color of the cell media.124 Therefore,
the amount of fluorescence produced is proportional to the number of viable and
metabolically active cells.
Using this AlamarBlue assay, the metabolic activity of HUVEC, NHDF, and
NHEK cells seeded on ARTISS, fibrin foam, or polyurethane foam was evaluated. The
proliferation and metabolism of each cell type was indicated as the fold-increase of the
AlamarBlue reagent at each time point (2, 24, 48, and 72 hours) using the excitation and
emission filters of 570 nm and 585 nm, respectively.
In Figure 21, Media Alone, Cell Lysis, fibrin foam (FF) alone, and PU foam
alone conditions all result in low fluorescence levels. This was expected as these
conditions are void of viable cells. Cells Alone, FF + Cells, ARTISS + Cells, and PU
Foam + Cells all begin to show a significant (p = 0.0304) increase in fluorescence at the 2
hour time point when compared to Media Alone. This significant difference carries
across all time points leading to the conclusion of continuously proliferating and
metabolizing cells present in these conditions, including fibrin foam. However, PU Foam
+ Cells had a significant decrease in fluorescence at 24 hours across all cell types when
compared to Cells Alone (p = 0.0304). Cells, in this instance, may have inhibited surface
adherence and migration into the polyurethane foam matrix, which would hinder their
proliferation.
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Figure 21. AlamarBlue Assay for Cellular Metabolic Activity. HUVEC, NHDF, and
NHEK cells were cultured similar to panel A and Alamar Blue (AB) reagent was
fluorescently analyzed at 2, 24, 48 and 72 hour time points. Media Alone, Cell Lysis, FF
alone, and PU foam alone conditions all result in low fluorescence levels. Cells Alone,
FF + Cells, ARTISS + Cells, and PU Foam + Cells all begin to show a significant (*p =
0.0304) increase in fluorescence at the 2 hour time point when compared to Media Alone.
This significant difference carries across all time points (2, 24, 48, and 72 hours) leading
to the conclusion of continuously viable and metabolizing cells present in these
conditions, including fibrin foam. However, PU Foam + Cells had a noticeable decrease
in fluorescence at 24 hours across all cell types. At 24 hours, PU Foam + Cells was
significantly different (#p = 0.0304) when compared to Cells Alone. All samples were
repeated for n = 4.
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Additionally, cytoxicity of fibrin foam was assessed per ISO 10993-5.118 The
results of this experiment (Table 13) detail fibrin foam’s biocompatibility once again.
Taken together, these assays have shown that fibrin foam is biocompatible from both
cellular viability and cellular metabolism assessments. Conversely, the current wound
therapy product, polyurethane foam, displayed marked cellular death in the LDH assay,
followed by a decreased rate of cellular proliferation in the AB assay after 24 hours of coculture. This may be due to the more suitable pore size distribution of fibrin foam as
compared to polyurethane foam or due to the extracellular matrix-like ligands present in
the foam’s structure.
Sample
Results/Score
Rating
Fibrin foam 1
0
Pass
Fibrin foam 2
0
Pass
Fibrin foam 3
0
Pass
Fibrin foam 4
0
Pass
Fibrin foam 5
0
Pass
Fibrin foam 6
0
Pass
Table 13. ISO 10993-5 Cytotoxicity Assessment of Fibrin Foam. Results from the
ISO 10993-5 assessment of fibrin foam. All fibrin foam samples (n = 6) passed the
cytotoxicity analysis. The positive control (n = 3) failed in all of its tests; while the
negative control (n = 3) passed in all tests. Scoring and ratings are detailed in the
Methods section.
Along with the quantitative analyses of cellular biocompatibility, two qualitative
experiments were performed on fibrin foam. First, SEM images were taken of ARTISS
fibrin sealant and fibrin foam clots that were seeded HUVEC, NHDF, and NHEK cells.
These cells were cultured on the clots for 24 hours prior to imaging. As the images in
Figure 22 show, endothelial, fibroblast, and keratinocyte cells spread and have
morphology associated with viability on the ARTISS fibrin clots in panels A-C. When
compared to the lower panels (D-F), the identical morphologies in the cell types are seen
in and on the fibrin foam clots.
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Figure 22. Cellular Interactions with Fibrin Foam. Cellular interactions with fibrin
foam. Scanning electron microscopy images of ARTISS fibrin sealant (top) and fibrin
foam (bottom) seeded with HUVEC (A, D), NHDF (B, E), and NHEK cells (C, F). Cells
were cultured for 24 hours on the fibrin clots before fixation. Scale bars: 50 µm. FF:
fibrin foam, HUVEC: human umbilical vein endothelial cells, NHDF: normal human
dermal fibroblasts, NHEK: normal human epidermal keratinocytes. Images are
representative of at least three separate images.
Additionally, cellular viability was assessed using confocal microscopy and
live/dead cell stains. HUVEC, NHDF, and NHEK cells were seeded on fibrin foam clots
and allowed to culture for 24 hours prior to imaging. After 24 hours, cells and clots were
stained with live/dead stain and a wheat germ agglutinin stain (WGA, stained fibrin foam
structure). Figure 23 confocal images show the vast majority of cells to be living (blue
stain) within the fibrin foam matrix for each cell type used.
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Figure 23. Cellular Viability Assessment of Fibrin Foam using Confocal
Microscopy. Confocal images of fibrin foam seeded with A) endothelial cells
(HUVEC), B) fibroblasts (NHDF), and C) keratinocytes (NHEK) following 24 hours of
incubation at 37°C / 5% CO2. Blue (live cell stain), green (dead cell stain), and orange
(wheat germ agglutinin). FF: fibrin foam, HUVEC: human umbilical vein endothelial
cells, NHDF: normal human dermal fibroblasts, NHEK: normal human epidermal
keratinocytes. Scale bars: 200 µm. Images are representative of three separate
experiments.
Aim 2: To evaluate the performance of fibrin foam as a novel dressing in acute
wound and negative-pressure wound therapy settings.
Three-dimensional in vitro wound model. The structure and porosity of fibrin
foam coupled with its biocompatibility and biodegradability make it a suitable candidate
for wound therapy. Additionally, host cell migration into such wound scaffolds in vivo is
crucial for such processes as angiogenesis and skin regeneration to occur. In this part of
the research, a three-dimensional in vitro wound assay was employed to visually assess
cellular migration into and onto fibrin foam.125 For this in vitro assay, I utilized a threedimensional (3D) model which mimics that of a skin wound environment. This allowed
me to study the cellular migration of cells in the wound where previous 2D assays have
sufficiently lacked. This 3D model was generated using a collagen matrix to mimic skin.
Once the matrix was formed, HUVEC, NHDF, and NHEK cells were stained and seeded
on the collagen before a wound was created in the matrix using a 2 mm biopsy punch.
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The wound defect was filled with one of four treatments – collagen (control), ARTISS
fibrin sealant, fibrin foam, or polyurethane foam.
At 24 and 48 hours after treatments were applied, the 3D wounds were
fluorescently imaged. As seen in the top panel of Figures 24-26, the control-treated
wounds had visibly poor cell migration onto their surface at both time points. The lack of
fluorescent cells migrating onto the collagen-filled matrix is shown across all three cell
types. Similarly, polyurethane (PU) foam-treated wounds (lower panels in figures) had
marked failure of cellular adherence to its matrix or migration into the polyurethane foam
dressing. From the fluorescent images of the PU foam-treated wounds, the presence of
sloughed, or likely dead, cells that had settled into the bottom of foam matrix was noted –
likely due to improper attachment to the synthetic polyurethane foam scaffold.
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Figure 24. Three-Dimensional In Vitro Wound Assay (NHDF). Endothelial (HUVEC)
cells, fibroblasts (NHDF) (shown), and keratinocytes (NHEK) stained with Vybrant DiO
were analyzed for migration. Biopsy punch (2 mm) wounds were filled with control
(PureCol EZ Gel), ARTISS fibrin sealant, fibrin foam, and polyurethane foam dressing.
Migration was assessed at 24 and 48 hours into and onto wound treatments. Images are
labeled with white arrows to denote location of wound periphery. A representative image
of an unfilled wound is shown in the upper left corner. Location of treatments noted by
abbreviations: C: Control; A: ARTISS; FF: Fibrin Foam; PU: Polyurethane foam
dressing. Images were taken at 4x magnification. Images are representative of at least
three separate samples.
Conversely to the control- and PU foam-treated wounds, moderate cell migration
was seen at both time intervals for ARTISS fibrin sealant. When imaged, ARTISS led to
a cloudy appearance in the wound cavity as is noted in its macroscopic form as well (Fig.
10). However, wound margins were still able to be marked (white arrows) for reference.
Each cell type was able to adhere to the ARTISS fibrin matrix and was able to migrate
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onto its surface by the 48 hour time interval. Lastly, fibrin foam-treated wounds showed
and allowed for the greatest migration of cells into the foam-filled wound margin with all
three cell types and at each time point. From the fluorescent images, migration of cells
into and onto the fibrin foam scaffold can be seen.
Through the use of this assay, this research was able to recreate a threedimensional collagen-based wound in vitro and test the efficacy and performance of
several wound treatments. From a qualitative standpoint, fibrin foam-treated wounds
were shown to allow for a more favorable migration environment throughout this 3D in
vitro wound assay due to its fibrin matrix and porous structure.

91

Figure 25. Three-Dimensional In Vitro Wound Assay (HUVEC). Three-Dimensional
In Vitro Wound Assay. Endothelial (HUVEC) (shown) cells, fibroblasts (NHDF), and
keratinocytes (NHEK) stained with Vybrant DiO were analyzed for migration from
collagen matrix (PureCol EZ Gel) into 2 mm biopsy punch wound. Biopsy punch
wounds were filled with control (PureCol EZ Gel), ARTISS fibrin sealant, fibrin foam,
and polyurethane foam dressing. Migration was assessed at 24 and 48 hours into and
onto wound treatments. Images are labeled with white arrows to denote location of
wound periphery. A representative image of the unfilled wound is shown in the upper
left corner. Location of treatments noted by abbreviations: C: Control; A: ARTISS; FF:
Fibrin Foam; PU: Polyurethane Foam dressing. Images were taken at 4x magnification.
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Figure 26. Three-Dimensional In Vitro Wound Assay (NHEK). Three-Dimensional In
Vitro Wound Assay. Endothelial (HUVEC) cells, fibroblasts (NHDF), and keratinocytes
(NHEK) (shown) stained with Vybrant DiO were analyzed for migration from collagen
matrix (PureCol EZ Gel) into 2 mm biopsy punch wound. Biopsy punch wounds were
filled with control (PureCol EZ Gel), ARTISS fibrin sealant, fibrin foam, and
polyurethane foam dressing. Migration was assessed at 24 and 48 hours into and onto
wound treatments. Images are labeled with white arrows to denote location of wound
periphery. A representative image of the unfilled wound is shown in the upper left
corner. Location of treatments noted by abbreviations: C: Control; A: ARTISS; FF:
Fibrin Foam; PU: Polyurethane Foam dressing. Images were taken at 4x magnification.
Negative-pressure wound therapy (NPWT) feasibility using fibrin foam.
Negative-pressure wound therapy (NPWT) utilizes a vacuum system, which applies
subatmospheric pressures ranging from 0 to -300 mmHg, to improve wound healing.
This technique is often used in hard-to-close acute and chronic wounds because of its
ability to seal the wound edges, continuously remove excess exudate from the site of
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injury, and promote wound healing. NPWT involves the use of polyurethane foam or
gauze dressings to cover and fill the wound site and serve as a permeable barrier. NPWT
is ever-growing in popularity for patients with skin grafts, dehisced surgical wounds, and
pressure ulcers as these clinical indications have increased during the 21st century.126,127
However, the disadvantage to treating such wounds with a polyurethane foam
dressing is the need to debride the wounds every 2 to 3 days of vacuum treatment.
During these few days, tissues are pulled and migrate into the non-biodegradable matrix
of the polyurethane foam. This debridement step in NPWT leads to pain and irritation to
the patient, re-injuring of the wound site, and an overall decrease in the wound healing
rate.128 Therefore, I wanted to test the feasibility of fibrin foam for use in a NPWT
environment. Fibrin foam holds a porous matrix to allow for removal of exudate from
the wound; however, fibrin foam also generates a fibrin scaffold for the migration of cells
and tissues. Lastly, fibrin foam is a biodegradable and biocompatible matrix and
therefore would not need to be debrided from NPWT-treated wounds.
For NPWT feasibility, full-thickness biopsy punch wounds were created in
porcine skin samples. The wounds were filled with fibrin foam or ARTISS and allowed
to cure over several time points. After curing, the NPWT device (KCI, Inc.) was
attached, a protective plastic sheath was placed over the treated wound, and
subatmospheric pressure (-200 mmHg) was applied to the wounds for 2-5 minutes. At
each time point, images were taken. As Figure 25B and 25E shows, fibrin foam was able
to withstand the negative pressure and remain in the wound cavity. To test the worst-case
scenario (Fig. 25C, 25F), the protective sheath was removed and the direct pressure from
the vacuum system was placed on top of the fibrin foam-treated wound. As seen at this
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instance as well as the remaining time points, fibrin foam remained within the wounds
after treated with the NPWT system. As shown in Figure 28, I also tested the feasibility
of ARTISS fibrin sealant for use in NPWT. Similarly to fibrin foam, ARTISS remained
in the wound cavity at 30 minute, 1 hour, and 2 hour time points.

Figure 27. Negative-Pressure Wound Therapy Feasibility with Fibrin Foam. A)
Negative-pressure wound therapy vacuum system apparatus attached to a 12-mm biopsy
punch porcine skin wound treated with fibrin foam. B/E) Fibrin foam-treated wound
after 30 minutes of set time followed by 2-5 minutes under negative pressure (-200
mmHg). C/F) Fibrin foam-treated wounds after 30 minutes of set time followed by
application of vacuum directly onto wound. D/G) Fibrin foam-treated wounds after 1
hour and 2 hour set times, respectively, followed by application of vacuum treatment. In
each instance, fibrin foam remained within wound cavities.
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Figure 28. Negative-Pressure Wound Therapy Feasibility Testing with ARTISS.
Negative-Pressure Wound Therapy Feasibility for ARTISS fibrin sealant. Images taken
at 30 minutes, 1 hour, and 2 hours after ARTISS treatment of wound punch biopsies (A,
B, C). At each time point, negative pressure (-200 mmHg) was applied for 2-5 minutes
using negative pressure vacuum system. Wound images were taken after the application
of NPWT (D, E, F). ARTISS remained in wounds at each time point after application of
NPWT. Three wounds were treated at each time point.
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In vivo murine model assessment of fibrin foam. Since this research had
characterized fibrin foam and shown the feasibility of the foam as a wound therapy in
vitro, I wanted to evaluate its in vivo wound healing abilities. To accomplish this, I
utilized a full-thickness murine wound biopsy punch model in collaboration with Loyola
University Chicago and the W. Keith Jones Laboratory. The BKS.Cg-Dock7m +/+
Leprdb/J (db/-) mice (8-12 weeks of age) were anesthetized, and a 6 mm biopsy punch
was used to make four excision wounds (1 cm apart) on the dorsal surface of the animal.
Each of the four wounds was treated separately and covered using experimental materials
and dressings, including ARTISS, fibrin foam (FF), polyurethane (PU) foam, and control
(no treatment) (Figure 11).
To assess the wound closure of each treatment, a digital camera was used to take
photographs of the wounds at days 0, 3, 7, 10, and 14. From the photographs taken, the
wound area was measured. A wound was considered completely closed when the wound
area was equal to zero (grossly). FIJI ImageJ imaging software was used to measure the
wound area using manual technique as previously described.119 Briefly, wound area was
assessed by tracing the wound area with a fine-resolution computer mouse and
calculating the pixel area within. The wound closure analysis was performed blinded and
only the mouse identification number was known.
In general, the healing rate of fibrin foam-treated mice was greater than those of
the other three treatments (Fig. 29). At day 7, fibrin foam-treated mice demonstrated
significantly accelerated wound closure when compared to control (p = 0.045), ARTISS
(p = 0.007), and PU (p < 0.001). Similar results were noted at day 14, when fibrin foamtreated wounds healed with wound closure significantly greater than the other treatment
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groups (p < 0.05). This data indicates the fibrin foam wound therapy improved wound
closure, which resulted in an overall better wound healing effect on the animals. Wound
closure was also calculated based on percent wound closure based on day 0 wounds as
100% open. The results were identical as fibrin foam still showed significant ability to
close the murine wounds compared to all other treatments (Fig. A2). Fibrin foam-treated
wounds also yielded the most fully-closed wounds as detailed by the Loyola surgical staff
at day 14. Fibrin foam had 5 fully-closed wounds (of 12 total mice) compared to 2 of
control, 1 of ARTISS, and 0 of polyurethane foam (data not statistically significant).
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Figure 29. Fibrin Foam Performance in Murine Wound Model. A) Initial wound
sizes (cm2) were equivalent for the four treatments but significantly different subsequent
days (p < 0.001 for days 3-14). By day seven, wounds treated with fibrin foam (FF) were
smallest compared to all other treatments (*p < 0.05). Wounds were significantly larger
for polyurethane foam (PU) compared to the other treatments (#p < 0.001). C) At day 14,
initial wound sizes were similar for all treatments. Similar to day 7, wounds were
significantly larger for PU compared to all other treatments (#p < 0.001) at day fourteen.
Wounds treated with fibrin foam were significantly smaller compared to the other
treatments (*p < 0.05). Twenty-four mice were analyzed for panel A and twelve mice
were analyzed in panel B.
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To obtain a further understanding into the tissue regeneration in the biopsy punch
wound site, hematoxylin & eosin (H&E) and Masson’s Trichrome staining were
performed at Loyola to assess the cellular change of the skin throughout the wound
model. At days 7 and 14, wounds were assessed on several histological parameters. The
main histological parameters for wound healing were: reepithelialization, neovascular
proliferation, acute and chronic inflammation, and collagen deposition. These parameters
were scored on a 0-3 scale as shown in Table 8.120 Additionally, epithelial maturation,
granular tissue formation, and granular tissue maturation were assessed on a yes-or-no
basis. The degree of granular tissue formation/maturation was determined by the
structure and alignment of fibroblasts in the wound area.
Representative histological images of wounds from days 7 and 14 are shown in
Figure 30. As the H&E staining details, fibrin foam-treated wounds had already begun
the processes of reepithelialization and granular tissue formation by day 7 (Fig. 30C), and
these wounds exhibited almost complete wound closure by day 14 (Fig. 30G). This was
comparable to ARTISS and control based on histological samples. However, the
polyurethane foam-treated wounds showed lack of epithelialization as clearly noted in
Figure 30D and 30H. The polyurethane foam matrix is wedged within the wound cavity,
and upon debridement, leads to re-injuring of the wound site.
Collagen deposition was also assessed using Masson’s Trichrome stain. Figure
31 shows representative images of day 14 wounds from each treatment group. Control
(31A) and fibrin foam (31C) treated wounds showed an abundant level of collagen
deposition. This is in contrast to the polyurethane foam-treated wound (31D) which
showed scant deposition of collagen by day 14 as these wounds failed to properly heal.
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Figure 30. Histological Assessment of Murine Acute Wounds. Images of wound
specimens from each wound treatment group at day 7 (top panel) and day 14 (bottom
panel) using H&E stain. Sections were prepared and stained as per methods. A/E)
Section from a wound from Control treatment group; B/F) Section from a wound from
ARTISS treatment group; C/G) Section from a wound from Fibrin Foam treatment group;
D/H) Section from a wound from Polyurethane Foam dressing treatment group. The
scoring for the wound healing parameters for these samples with respect to
reepithelialization, neovascular proliferation, and acute and chronic inflammation were,
respectively: A) 0, 1, 0, 2 B) 2, 1, 1, 1 C) 2, 3, 1, 2 D) 1, 1, 3, 2 E) 3, 2, 1, 1 F) 3, 1, 1, 1
G) 3, 3, 1, 1 H) 0, 1, 3, 2. E: epithelium; D: dermis; G: granulation tissue; S:
subcutaneous tissue; M: muscle. Scale bars: 700um.
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Figure 31. Collagen Deposition Analysis of Wound Samples. Images of day 14 wound
specimens from each treatment group using Masson’s Trichrome stain for collagen
deposition. A) Section from control group wound B) Section from ARTISS group wound
C) Section from fibrin foam group wound and D) Section from polyurethane foam group
wound. The scoring of collagen deposition was, respectively: A) 3 B) 2 C) 3 D) 1.
Scale bars: 500 µm.
The histological slides from Figures 30 and 31 were blindly assessed by a Loyola
pathologist on the aforementioned parameters. The raw data of these results are found in
Table A2 and A3, while the graphical data is shown below in Figures 32 and 33. Figure
32 details a comparison of the parameters – reepithelization, neovascular proliferation,
acute and chronic inflammation, and collagen deposition – at days 7 and 14. While none
of the comparisons were found to be significant, the data is useful for determining the
cellular and wound-healing responses to the fibrin foam matrix and the other treatments.
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Figure 32. Histological Comparisons of Wounds at Days 7 and 14. Histological
analyses at days 7 (A, C, E, G, I) and 14 (B, D, F, H, J) from Tables A2 and A3. n = 12
for all groups, except collagen deposition (n = 6).
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From Figure 32, the parameters and scoring for the wounds treated by fibrin foam
were further assessed. The green bars, representing fibrin foam-treated wounds, show a
sharp increase in reepithelization from day 7 to day 14 (Fig. 32A, 32B). Additionally,
these wounds have revascularization occurring at both time points, which is a hallmark of
proper wound healing. Similarly, collagen deposition increased in fibrin foam wounds
over the two week period. While inflammation is necessary in proper wound healing, an
abundance or prolonged periods of inflammation can lead to improper or chronic wound
healing. As shown in Figure 32E-H, fibrin foam wounds have scores of 0-1 for acute and
chronic inflammation over the study. There were no signs of prolonged inflammation in
the fibrin foam-treated wounds.
ARTISS and control treated wounds also showed similar results to fibrin foam in
the five categories of Figure 32. Polyurethane foam, however, had distinct lack of proper
wound healing parameters, including sustained inflammation and lack of collagen
deposition over the two weeks.
Lastly, granular tissue formation and maturation as well as epithelial maturation
were assessed. Figure 33 representatively details the results of that analysis. While no
significance was observed, trends of increases in granular tissue maturation and epithelial
maturation were noted for the fibrin foam-treated wounds over the 14-day study. Again,
this signifies proper wound healing processes occurring within the wounds treated with
fibrin foam.
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Figure 33. Quantification of Histological Data from Murine Model. Positive
observations (YES/NO outcomes) for the histological and pathological parameters of
epithelial maturation, granular tissue formation, and granular tissue maturation at days 7
and 14 from Tables A2 and A3 (n = 12 per group).
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As shown, the polyurethane foam-dressed wounds produced the worst histological
response as noted by the lack of reepithelialization and other features (Fig. 30). This
result goes in line with the wound closure data (Fig. 29), which showed PU-treated
wounds had the significantly poorest wound closure when compared to any other
treatment (p < 0.001). This was due to the debridement of the wounds on dressingchange days – a typical clinical disadvantage to use of non-biodegradable dressings. I
chose to analyze the debrided polyurethane foam on dressing-change days. In Figure 34,
H&E staining of debrided polyurethane foam dressings was performed. The debrided
dressings contained skin and tissue on the periphery as well as intercalated within the
polyurethane foam matrix at both days 7 and 14. This confirmed previous observations
in literature as to one of the key disadvantages of polyurethane foam dressing use in
clinical situations – debridement.
From the combined in vivo analyses, the fibrin foam-treated wounds exhibited
vastly improved wound healing and were able to provide an environment suitable for
wound healing processes, such as reepithelialization and granulation tissue formation and
maturation.
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Figure 34. Histological Assessment of Debrided Polyurethane Foam Dressings.
Images of A) day 7 and b) day 14 debrided polyurethane foam dressings from the
polyurethane foam treatment group using H&E stain. Images show tissue embedded into
the polyurethane foam matrix, which was debrided from each wound. Scale bars: 2 mm.

CHAPTER FIVE
DISCUSSION
Wound care is an impactful clinical and economical issue. In the United States
alone, patients suffer from over 38 million acute and 6.5 chronic wounds each year.8 Due
to this ever-growing clinical problem, wound care has evolved significantly from gauze
and sutures to regenerative dermal substitutes and implanted stem cells. Wound healing
is a complex process that involves a vast array of cells, growth factors, and cellular
matrices.7,9 To treat the multifaceted wound healing process, tissue engineering
researchers have devoted their efforts to finding an efficient and enhanced wound
therapy. However, an optimal wound therapy still escapes the scientific and medical
communities. Current research in the fields of tissue engineering and wound therapy are
vying for the ideal therapy. This therapy must include the following features:
biocompatible with tissues, biodegradable, mechanically suitable for wound cavity and
movement, and permeable to cell and fluid transfer, among others. Certain scaffolds,
such as collagen, polyesters, and fibrin have been studied in great detail.10 Fibrin
sealants, for instance, have been investigated as a wound healing matrix due to their
functioning as a critical treatment methodology in hemostasis, inflammation,
angiogenesis, and cellular interactions – all hallmarks of proper wound healing.16
In the present study, I describe a novel biopolymer – fibrin foam – that is
generated through a patented aeration mixing process using a commercially-available
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fibrin sealant.24-27 Fibrin foam is created by manually passing fibrinogen and thrombin
components through a porous, sintered mixing disc (Fig. 9A). Its foam-like consistency
and porous structure are formed through the addition of air prior to mixing. Fibrin foam
was characterized on several levels, including preparation and formulation,
biocompatibility, and biomechanical strength. I also showed its use as a superior therapy
in a murine wound model.
Initial tests on fibrin foam assessed the preparation and formulation to devise an
optimal foam. I experimented with the number of manual passes to generate fibrin foam
as well as the thrombin concentration and other additives. The requirements for the foam
were that it must be easily handled during preparation, have a foam-like consistency, and
have a pore size distribution < 200 µm. The manual mixing tests revealed a 4 IU
thrombin fibrin foam generated from 6 passes through the Mix-F device to be the optimal
foam (Fig. 13, Table 10). This foam met the requirements and would allow for ease of
preparation by medical professionals in a wound therapy situation.
The biomechanical and structural properties of a biomaterial are crucial for use in
wound care. Many studies have detailed the performance characteristics of effective
wound therapies, including substantial tensile strength to remain in a wound cavity, but
also the elasticity to move with the tissue throughout the healing process. I thereby
assessed the tensile and wound closure strengths of fibrin foam. A decrease in strength
was noted when compared to the fibrin sealant (Fig. 18A, 18C). This was hypothesized,
however, as the aeration process leads to a more open matrix, which could cause this
weakening effect on its structure. The elasticity of fibrin foam was significantly superior
to that of the sealant (Fig. 18B).
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Along with strength and elasticity, an optimal wound therapy must also have
sufficient permeability and a porous structure to allow for both fluid and cellular
movement. Shown in Table 12, structural analyses were performed on fibrin foam and
ARTISS. Fibrin foam’s compaction was significantly higher than that of ARTISS, which
correlates to its aerated and porous state compared to the denser fibrin network of
ARTISS. Fibrin foam also had increased porosity and permeability, as I would expect
given its structure. These qualities are vast improvements from that of commerciallyavailable fibrin sealants and are advantageous to promoting an enhanced wound healing
response. Lastly, to examine the biodegradability of fibrin foam, an in vivo murine
model was used to assess the degradation of fibrin foam over a two-week span. Similar
degradation of fibrin foam was noted when compared to fibrin sealant; the porous
structure of fibrin foam did not cause any increase (or decrease) in biodegradability,
which gives confidence to the use of fibrin foam as an in vivo therapy (Fig. A1).
Next, I tested the in vitro biocompatibility of fibrin foam. Biocompatibility of the
foam was expected, as its material composition is identical to the commercialized fibrin
sealant, ARTISS, with demonstrated biocompatibility. However, the effects of aeration
had not been previously studied. Thus, fibrin foam was confirmed as highly
biocompatible through the use of SEM and confocal microscopy (Figs. 22, 23) as well as
the cellular viability assays (Figs. 20, 21).
After characterizing the optimal preparation of fibrin foam, it was assessed in an
in vitro wound assay using 3D collagen matrices. Fibrin foam qualitatively showed the
greatest migration of cells into and onto its matrix. ARTISS also promoted migration of
cells onto its surface; however, the more porous foam allowed for greater cellular
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penetration into the wound space as compared to ARTISS (Figs. 24-26). Moving from
these promising results from the characterization, I studied the use of fibrin foam as a
novel wound therapy in an acute murine wound model. BKS.Cg-Dock7m +/+ Leprdb/J
(db/-) mice were used due to their genetic background. These mice have the same
genetic background as diabetic mice (db/db); however db/- mice do not exhibit the
diabetic phenotype. The db/- mice were used as a gateway to study diabetic and impaired
wound healing models in future animal work.
As seen from the murine model, at days 7 and 14, fibrin foam promoted
significantly increased wound closure when compared to control and other wound
treatments (Fig. 29). This superior ability of fibrin foam can be attributed to several
factors. First, the fibrin-based foam is an optimal matrix for a wound site. Fibrin has
been studied greatly for its interactions with extracellular matrices, keratinocytes,
fibroblasts, and other major cellular components of the wound healing process.16 These
interactions are both integrin and non-integrin (e.g. VE-Cadherin, P-selectin, and I-CAM1) receptor driven. Fibrin foam also possesses a pore size distribution that is applicable
to the migration of these same wound healing cells and infiltration of cellular factors.
Lastly, the inherent hemostatic ability of fibrin foam lends itself to actively supporting
the pathways of hemostasis and the coagulation cascade – the first phase of wound
healing.
The same trend and significance in wound closure was seen when wound closure
was computed based on a percentage of day zero wound size (Fig. A2).
Immunohistochemistry was analyzed to assess the host’s reaction to the different wound
treatments. The histological analysis showed an efficacious response to fibrin foam
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(Figs. 30-33). While no significance was noted from analyzing the histological parameter
scores of each treatment group, reepithelialization, granular tissue formation/maturation,
and collagen deposition were all abundant in the fibrin foam-treated wounds.
Along with the in-depth comparisons of fibrin foam to its parent fibrin sealant, I
also assessed the differences between fibrin foam and a current acute and chronic wound
treatment, polyurethane foam. Polyurethane foam dressings are often used in these
instances for their ability to provide a porous matrix (400-600 µm pores), which allows
for high fluid and cellular transfer in a wound healing situation. A clinical drawback to
these dressings is that they are non-biodegradable structures that must be debrided from
wound sites at periodic time intervals.126,127 In each of the characterization experiments
as well as the in vitro and in vivo models, fibrin foam had significantly different attributes
when compared to polyurethane foam, including its increased porosity, ideal pore size
distribution, and better biocompatibility. This led to the testing of the feasibility of fibrin
foam for use in negative-pressure wound therapy (NPWT). NPWT is a current vacuumbased wound therapy that utilizes polyurethane foam dressing or gauze as a wound
healing treatment. The results, shown in Figure 27, detailed the ability of fibrin foam to
remain within a wound cavity after application of subatmospheric pressure system.
Fibrin foam was able to remain in the wounds over several time intervals as well.
The overall effectiveness of fibrin foam compared to the commercially-available
fibrin sealant and polyurethane foam is, I believe, dependent on the hybridization of a
fibrin-based scaffold and a structural matrix of pores suitable to sustain a wound healing
environment. The fibrin portion of the foam allows it to facilitate the critical aspects of
the wound healing process, such as cellular interactions and functioning in hemostasis
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and angiogenesis. Additionally, the aeration process through the patented Mix-F mixing
device allows for the generation of a porous scaffold with pore size distribution (100-250
µm), porosity, and permeability that is able to support cellular proliferation and migration
that is not seen in either commercially-available fibrin sealants (0-50 µm) or
polyurethane foam dressings (400-600 µm) (Fig. 35).
Taken together, this presented research has characterized a novel fibrin
preparation. The optimal fibrin foam preparation has proven to meet and exceed the
requirements needed for an effective wound therapy in today’s clinical atmosphere. The
fibrin-based biopolymer is: prepared with ease, biocompatible with cells and tissue,
biodegradable in vivo, possesses mechanical strength and elasticity for wound closure,
allows for fluid and cell infiltration, and reduces healing time – all hallmarks of an
optimal wound therapy. These combined qualities were ever-apparent in the murine
wound model, where fibrin foam was significantly superior to all other treatments and
resulted in positive wound healing in all mice.
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Figure 35. Fibrin Foam Functioning in Wound Healing. Fibrin foam (6 passes + 4
IU) preparation contains a pore size range from approximately 100-250 µm as compared
to fibrin sealant (0-50 µm) and polyurethane foam dressings (400-600 µm). Due to this
pore size spectrum within then fibrin foam matrix, key cellular processes could find fibrin
foam a suitable environment. Additionally, fibrin foam contains specific wound-healing
attributes and added hemostatic influence (derived from fibrin sealant components) that
generates a suitable wound therapy. SMC: smooth muscle cell.
Future Directions.
The results from this dissertation research present several possibilities for further
investigations. First, additional experiments can be done to delve deeper into the vast
potential of fibrin foam and its preparation and formulation. Within this study, I was
restricted to the Mix-F and Vyon-F devices to generate fibrin foam (Fig. 9). This mixing
apparatus allowed for only a finite number of manual passes to be performed, while also
limiting the constituents that could be passed through the porous Vyon-F. As mentioned,
the addition of HSA and Tween 80 as well as increased thrombin concentrations were, in
some instances, prevented by the mixing apparatus due to clogging.
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Permutations to the Vyon-F porous disc (i.e. increasing its porous structure) could
allow for mixing and aeration of more viscous preparations of fibrin foam. The addition
of HSA, Tween 80, or other surfactants may allow for a far greater foaming process to
occur during the mixing process. In preliminary work on fibrin foam, I assessed the total
foamed volume as compared to the volume of constituents used to generate the foam. In
these experiments, there was no noted increase in foam growth or expansion (data not
shown). An expanding foam, however, even one with faster clotting abilities, would be a
highly attractive medical therapy. Traumas that occur in combat, for instance, could use
a foaming hemostat and wound healing agent for severe bleeds and amputations.
It must be noted that ultimately the foam presented in this research becomes a
rigid structure due to the fibrin clot formation immediately following the mixing process
and application. While drainage and coarsening occur within the foam, the fibrin
structure holds strong until, and with in vivo situations, the fibrin is ultimately degraded
by proteolysis and fibrinolysis. Thus, fibrin foam forms a quasi-foam – aeration and the
presence of liquid/surfactant allows for the foam generation; however, after the initial
mixing process (lasting only seconds), the fibrin fibers begin to clot yielding the set,
foamed fibrin matrix.
While generating a larger foamed matrix or one that sets faster, could be
beneficial to cover more wound space in vivo or stop a larger bleed, respectively, fibrin
foam may also take on additional constituents to be used in a multitude of clinical
applications. Fibrin sealants have been supplemented with living cells, growth factors,
cytokines, and pharmaceutical drugs.16,87,89,90 Future studies spiking fibrin foam with
such growth factors, as platelet-derived growth factor (PDGF) or fibroblast growth factor
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(FGF) could allow for improved wound healing over what has already been seen within
this research. These factors would allow for the recruitment and activation of cells to
promote a wound healing response at the site of fibrin foam application. Vascular
endothelial growth factor (VEGF) is another potential candidate to supplement into fibrin
foam. With VEGF, fibrin foam could have added abilities to promote increased
neovascularization within a wound as well. Supplementation of wound-specific cell
types, such as keratinocytes and fibroblasts, is another possibility for use of the foam.
Outside of the realm of wound healing, fibrin foam could be subjected to the
addition of bone morphogenic protein (BMP) or human mesenchymal stem cells to aid in
the regrowth of cartilage and bone and differentiation into osteoblasts, respectively. A
final example could be the addition of antibiotics or other pharmaceutical drugs to fibrin
foam. Antibiotics could be used to prevent bacterial infection in any number of surgical
situations, while drugs, such as analgesics or anti-cancer medications could be added into
fibrin foam for improved treatment of patients. The options for further additives are
plentiful.
While the animal model showed significant results in favor of fibrin foam, there
are some additional experiments that need to be performed to properly assess fibrin
foam’s efficacy in vivo. Mice are a highly-used species for animal models and
translational research due to their ability to produce reproducible data, generate large
sample sizes, and can be manipulated genetically with ease. Mice also share over 95% of
genes with the human species. However, and in wound healing, mice heal through a
contractile process as opposed to reepithelization (humans).129 In the animal model, I
was not as concerned with this caveat, as one of the key portions of this research was to
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study the ingress of cells and tissues into the fibrin foam matrix and other treatments.
Additionally and to adjust for possible error, treatments were blindly and evenly rotated
on the dorsal surfaces of each mouse within the study. Future studies could also use a
splinted-wound murine model whereby the epidermis is held back via splints to prevent
the contractile healing response.119 Instead, these mice are forced to heal by
reepithelialization, which would better mimic the wound healing processes of humans.
The shown animal model also utilized the BKS.Cg-Dock7m +/+ Leprdb/J (db/-) mouse
strain, which has the same genetic background as their counterpart db/db mice that
possess a diabetic phenotype.119 These db/db mice would be subjects of further studies in
a similar wound model. The db/db mice, in this instance, heal slower and have traits of
chronic wound healing. Thus, the use of these mice would allow for preliminary in vivo
research on fibrin foam as a chronic wound therapy, and this data could be compared
back to their db/- littermates.
An additional animal study that would need to be performed to assess the validity
of fibrin foam as a novel wound therapy would be a larger animal study. Pigs would be
used, as porcine skin structure is highly similar to that of humans and correlates greatly.
Alterations to the histological parameter assessment would also be performed, as this
study lacked significance within the histology and pathology analyses of the treated
wounds. These changes would include an expanded scoring scale for the histological
parameters and immunohistochemical analysis of the wounds. The scoring scale used in
this research were scored from 0-3 (Table 8) or on a yes-or-no basis. While these scales
allowed for an overall assessment of the wound histology, a more detailed scale could
elucidate differences among the treatments. Furthermore, the use of
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immunohistochemistry to study the wound samples could be advantageous to gain a
better understanding of the wound environment under each treatment. Antibodies, such
as anti-Loricrin and CD28, could be utilized to stain for epidermal cell differentiation and
angiogenesis, respectively.130 Combined, these multiple animal studies would provide
deep insight as to the efficacy and performance of fibrin in not only acute wounds, but
chronic as well.
Fibrin foam was also tested for its use as a novel therapy in NPWT, since the
foam showed superior wound healing abilities over the current dressing, polyurethane
foam. While the in vitro feasibility results were positive, the next steps would require an
animal model. A similar biopsy punch model performed on pigs would allow for the
utilization of the actual NPWT vacuum system in vivo. Fibrin foam would be applied to
the pigs after wounding, the vacuum system would be applied for several days, and
wound healing would be compared to polyurethane foam. This experiment would be
crucial for the overall efficacy assessment of fibrin foam for use as a therapy in a NPWT
situation.
While fibrin foam seems to have abundant options in the clinical field, this
research has also shown some other promising results for future applications. As shown
in Figure 36, fibrin foam has the ability to be applied through laparoscopic applicators for
use in minimally-invasive and endoscopic surgeries. With successful manipulations to
the foam structure and/or clotting time, variations of the foam could be used
laparoscopically in gastrointestinal anastomoses, perforated ulcer treatment, and hernia
repair. Additionally, fibrin foam was able to be lyophilized and reconstituted to its native
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fibrin foam structure. The lyophilization process could allow for a longer shelf life and
quicker reconstitution, preparation, and application of fibrin foam at a wound site.

Figure 36. Additional Applications of Fibrin Foam. A) Fibrin foam usage through
Baxter endoscopic applicator onto an inverted surface, such as used in minimally
invasive surgeries. B/E) SEM images of lyophilized fibrin foam. C/F) SEM images of
reconstituted fibrin foam. D/G) SEM images of native fibrin foam. Scale bars: 100 µm
(B-D), 1 mm (E-G).
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Throughout this combined research, I demonstrated that the biodegradable fibrin
foam has unique macroscopic and microscopic structural characteristics from those of
typical fibrin sealants. The foamed scaffold generates greater porosity, increased fluid
permeability, and pore sizes suitable for cells and processes associated with a wound
healing environment. Fibrin foam was also shown to be biocompatible and proved to be
an efficacious and significantly superior acute wound healing treatment in both in vitro
and in vivo model systems. This research sheds light on a novel fibrin matrix and its
potential use as a wound therapy (Fig. 37). The results of this dissertation can also serve
as the basis to develop innovative treatments – utilizing variants of fibrin foam – for
specific surgical and regenerative medicine applications.

Figure 37. Fibrin Foam as a Novel Wound Therapy. An acute wound treated with the
novel biopolymer, fibrin foam. With its pore size distribution, fibrin network, and
wound-healing attributes, fibrin foam is a potential candidate for use in wound therapy.
Significance.
Wound healing products have been used in a variety of indications for many
years. From acute lacerations to chronic pressure ulcers, wound healing products, such as
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sutures and surgical sealants, have been the mainstay in this medical field. However,
each wound healing treatment comes with its own set of caveats and flaws.1 Sutures and
staples can often lead to dehiscence or infection in wound closure space; while
polyurethane foams can cause painful debridement from the tissues. An ageing
population and increased occurrence of chronic wounds are additional trends that are
affecting the wound healing field. Thus, the development and advancement of more
efficacious and safe products is a substantial need for current and future patients. This
research is significant because it served to improve the wound field by evaluating fibrin
foam in two-fold – through characterization of its physical and biological properties, and
analysis of the foam’s use as an innovative wound therapy.
This research is impactful because it was the first to look at characterizing and
understanding the unique set of qualities that fibrin foam possesses and how this
knowledge could be translated to the medical field. The previously-mentioned attributes
of the foam make it applicable for use in specific surgical and wound healing
applications. The greater viscosity allows for fibrin foam to be applied on vertical or
inverted surfaces, such as in laparoscopic surgeries or diabetic and pressure ulcer
treatments. The foam’s ability to polymerize independently of temperature is
advantageous for a wide array of surgeries as the foam could be generated in the
operating suite and be applied in a bodily cavity without the risk of altering the foam’s
structure and attributes.
Furthermore, the unique preparation method and characteristics of the foam
alleviates some of the issues clinicians have with the current product and treatment
options as well. The patented mixing device used for generation of the foam obviates the
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need for gas-powered spray devices that are used in current surgeries to produce foamlike substances. These gas-powered spray devices are contraindicated for their use near
open wounds and intravascular procedures due to the potential for thromboembolisms.23
Fibrin foam allows for a similar foaming structure without the need for the additional
surgical equipment.
This research has also provided a better understanding of novel aerated
biopolymer – a fibrin-based foam – as a wound therapy agent as well. Fibrin and surgical
sealants have been used as acute wound closure treatments for years. The benefits to
fibrin sealants are that they mechanically seal the wound, aid in the hemostatic phase of
wound healing, and are biocompatible and biodegradable. The foam’s structure is
important to understanding its potential significance in the wound healing field. Fibrin
foam’s open pore clot structure promoted migration and invasion of cells into the foam.
This elicited an improved wound healing response when compared to current treatments.
In the wound healing field, a specific treatment called negative-pressure wound therapy
(NPWT) utilizes polyurethane foam or gauze to cover the wound site to treat acute and
chronic wounds. Vacuum pressure is then applied to the site to mechanically seal the
wound. However, discomfort, pain, and impaired wound healing can result from the use
of the polyurethane foam or gauze dressings. Polyurethane foam dressing must be
periodically debrided from the wound, a process which disrupts the wound and can
remove healing tissue. Therefore, there is a critical need for a biodegradable wound
dressing in this therapy. The research here evaluated fibrin foam for its use in NPWT.
Fibrin foam’s matrix and wound-healing ability are beneficial for cells and tissues to
grow into the biodegradable foam under vacuum treatment.
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While this research was centered on understanding how fibrin foam is generated,
defining its key attributes, and assessing its function as a wound therapy in both acute
wound and NPWT models, the significance of the research is much greater. The
thorough analyses that were performed on fibrin foam will serve as a platform for the
foam’s use in other surgical fields. It is imperative to realize the foam’s full potential
while evaluating its concept as a wound healing treatment and beyond.

APPENDIX A
SUPPLEMENTAL DATA
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Parameter

ARTISS
fibrin
sealant

Fibrin
foam (6
Passes)

Fibrin
foam (4
Passes)

Fibrin
foam (8
Passes)

Fibrin
foam (6
Passes +
20IU)

R (clot
formation,
minutes)

0.6 ± 0.4

0.2 ± 0.0

0.2 ± 0.0

0.2 ± 0.1

0.2 ± 0.1

Fibrin
Foam (6
Passes +
10%
HSA)
0.2 ± 0.1

K (degree of
elasticity,
minutes)

4.5 ± 1.8

0.8 ± 0.0

0.8 ± 0.0

0.8 ± 0.0

0.8 ± 0.0

0.8 ± 0.0

Maximum
amplitude
(MA; clot
strength, mm)

85.0 ± 6.6 88.1 ± 1.8 87.3 ± 2.0 89.7 ± 1.0 86.4 ±
1.9

87.8 ±
0.9

G (shear
modulus,
kd/sec)

35.5 ±
18.9

38.0 ± 6.5 35.3 ± 7.4 43.8 ± 4.6 32.3 ±
5.5

36.2 ±
3.0

α-angle (clot
kinetics,
degrees)

49.8 ±
11.4

86.0 ± 0.7 84.4 ± 0.6 86.1 ± 0.4 87.5± 0.0

85.8 ±
0.3

Table A1. Thromboelastography Analysis of Fibrin Foam Preparations.
Thromboelastography (TEG) results obtained for fibrin foam and commercially-available
fibrin sealant, ARTISS. Parameters measured included: fibrin clot formation (R), degree
of elasticity (K), α-angle, and clot (MA) and shear strengths (G). Any other fibrin foam
preparations not listed were not feasible for TEG analysis due to clotting and viscosity
issues with the TEG test system.
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Figure A1. In Vivo Degradation Analysis of Fibrin Foam. Fluorescence of remaining
ARTISS fibrin sealant (left boxes) or fibrin foam (right boxes) at each time point is
presented in percent of day 0 fluorescence. Degradation of both materials followed a
sigmoidal pattern over the observational period of 14 days. No significant differences in
the degradation process were detected. n = 6 per group.
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Figure A2. Wound Closure Assessment of Fibrin Foam. Initial wound sizes
(considered 100% open) were equivalent for the four treatments but significantly
different subsequent days (p < 0.001 for days 3-14). A) By day seven, wounds treated
with fibrin foam (FF) were smallest compared to all other treatments (*p < 0.05).
Wounds were significantly larger for polyurethane foam (PU) compared to the other
treatments (#p < 0.001). B) At day 14, initial wound sizes were similar for all treatments.
Similar to day 7, wounds were significantly larger for PU compared to all other
treatments (#p < 0.001) at day fourteen. Wounds treated with fibrin foam were
significantly smaller compared to the other treatments (*p < 0.05). Twenty-four mice
were analyzed for panel A and twelve mice were analyzed in panel B.
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n (%)
0
1
Reepithelization
Artiss
3 (25.0)
5 (41.7)
Control
5 (41.7)
3 (25.0)
FF
2 (16.7)
4 (33.3)
PU
5 (41.7)
5 (41.7)
Neovascular
proliferation
Artiss
0 (0.0)
6 (50.0)
Control
2 (16.7)
5 (41.7)
FF
0 (0.0)
4 (33.3)
PU
0 (0.0)
3 (25.0)
Acute inflammation
Artiss
0 (0.0)
5 (41.7)
Control
0 (0.0)
8 (66.7)
FF
3 (25.0)
8 (66.7)
PU
0 (0.0)
3 (25.0)
Chronic inflammation
Artiss
0 (0.0)
7 (58.3)
Control
0 (0.0)
9 (75.0)
FF
2 (16.7)
8 (66.7)
PU
0 (0.0)
5 (41.7)
Collagen Deposition
Artiss
0 (0.0)
2 (50.0)
Control
0 (0.0)
3 (75.0)
FF
0 (0.0) 4 (100.0)
PU
3 (75.0)
1 (25.0)
Table A2a. Day 7 Mice Histological Assessment.

2

3

3 (25.0)
2 (16.7)
3 (25.0)
2 (16.7)

1 (8.3)
2 (16.7)
3 (25.0)
0 (0.0)

4 (33.3)
3 (25.0)
4 (33.3)
5 (41.7)

2 (16.7)
2 (16.7)
4 (33.3)
4 (33.3)

6 (50.0)
4 (33.3)
1 (8.3)
1 (8.3)

1 (8.3)
0 (0.0)
0 (0.0)
8 (66.7)

3 (25.0)
3 (25.0)
2 (16.7)
6 (50.0)

2 (16.7)
0 (0.0)
0 (0.0)
1 (8.3)

2 (50.0)
1 (25.0)
0 (0.0)
0 (0.0)

0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
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n (%) Yes
Epithelial Maturation
Artiss
1 (8.3)
Control
3 (25.0)
FF
5 (41.7)
PU
1 (8.3)
Granulation Tissue
Formation
Artiss
12 (100.0)
Control
10 (83.3)
FF
12 (100.0)
PU
12 (100.0)
Granulation Tissue
Maturation
Artiss
1 (8.3)
Control
1 (8.3)
FF
3 (25.0)
PU
2 (16.7)
Table A2b. Day 7 Mice Histological Assessment.
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n (%)
0
1
Reepithelization
Artiss
2 (16.7)
5 (41.7)
Control
0 (0.0)
3 (25.0)
FF
0 (0.0)
0 (0.0)
PU
2 (16.7)
2 (16.7)
Neovascular proliferation
Artiss
1 (8.3)
5 (41.7)
Control
0 (0.0)
7 (58.3)
FF
3 (25.0)
6 (50.0)
PU
1 (8.3)
5 (41.7)
Acute inflammation
Artiss
2 (16.7)
7 (58.3)
Control
3 (25.0)
7 (58.3)
FF
6 (50.0)
4 (33.3)
PU
1 (8.3)
3 (25.0)
Chronic inflammation
Artiss
0 (0.0)
7 (58.3)
Control
0 (0.0)
9 (75.0)
FF
3 (25.0)
9 (75.0)
PU
0 (0.0)
7 (58.3)
Collagen Deposition
Artiss
0 (0.0)
0 (0.0)
Control
0 (0.0)
0 (0.0)
FF
0 (0.0)
0 (0.0)
PU
0 (0.0)
3 (75.0)
Table A3a. Day 14 Mice Histological Assessment.

2

3

1 (8.3)
0 (0.0)
1 (8.3)
4 (33.3)

4 (33.3)
9 (75.0)
11 (91.7)
4 (33.3)

3 (25.0)
3 (25.0)
1 (8.3)
4 (33.3)

3 (25.0)
2 (16.7)
2 (16.7)
2 (16.7)

1 (8.3)
2 (16.7)
2 (16.7)
0 (0.0)

2 (16.7)
0 (0.0)
0 (0.0)
8 (66.7)

5 (41.7)
3 (25.0)
0 (0.0)
5 (41.7)

0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)

3 (75.0)
2 (50.0)
3 (75.0)
1 (25.0)

1 (25.0)
2 (50.0)
1 (25.0)
0 (0.0)
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n (%) Yes
Epithelial Maturation
Artiss
4 (33.3)
Control
10 (83.3)
FF
7 (58.3)
PU
5 (41.7)
Granulation Tissue
Formation
Artiss
12 (100.0)
Control
10 (83.3)
FF
11 (91.7)
PU
12 (100.0)
Granulation Tissue
Maturation
Artiss
9 (75.0)
Control
10 (83.3)
FF
9 (75.0)
PU
5 (41.7)
Table A3b. Day 14 Mice Histological Assessment.
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